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Abstract 
My PhD Thesis work, developed in Veneto Nanotech Laboratories (Nanofab in Marghera, LaNN in Padova 
and ECSIN in Rovigo), was aimed at the exploitation of the Surface Plasmon Resonance (SPR) phenomenon 
for the set-up of biosensing platforms for clinical and environmental applications. 
In particular, two types of SPR-based platforms were set-up and optimised: the first one was an 
oligonucleotide-based platform for the detection of Cystic Fibrosis (CF) causing mutations while the second 
one was an antibody-based platform for the detection of Legionella pneumophila whole cells. 
Both sensors are based on the same detection strategy, exploiting the advantages of using a highly sensitive 
Grating Coupled - Surface Plasmon Resonance (GC-SPR) enhanced spectroscopy method, designed using a 
conical illumination configuration for label-free molecular detection. 
Concerning DNA platform for Cystic Fibrosis, a strategy for the detection of some of the most frequent 
mutations responsible for CF among the Italian population is investigated. For the detection of the CF 
mutations, gold sinusoidal gratings are used as sensing surfaces, and the specific biodetection is achieved 
through the usage of allele specific oligonucleotide (ASO) DNA hairpin probes, designed for single 
nucleotide discrimination. Substrates were used to test unlabeled PCR amplified homozygous wild type (wt) 
and heterozygous samples (wt/mut) - deriving from clinical samples - for the screened mutations. 
Hybridisation conditions were optimised to obtain the maximum discrimination ratio (DR) between the 
homozygous wild type and the heterozygous samples. SPR signals obtained from hybridising wild type and 
heterozygous samples showed DRs able to identify univocally the correct genotypes, as confirmed by 
fluorescence microarray experiments run in parallel. Furthermore, SPR genotyping was not impaired in 
samples containing unrelated DNA, allowing the platform to be used for the parallel discrimination of 
several alleles also scalable for a high throughput screening setting. 
Concerning antibody platform for Legionella pneumophila bacteria detection, a strategy for the exploitation 
of the SPR phenomenon to develop a fully automated platform for fast optical detection of Legionella 
pneumophila pathogens was investigated. The legal limit of L. pneumophila in a high-risk hospital 
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environment in Italy is 102 CFU/L, and the gold standard for its identification is a time consuming 
microbiological culture method, that requires up to 7 days. 
Starting from these considerations a sensitive GC-SPR system was applied to the detection of L. 
pneumophila to test the detection limit of the developed sensing device in term of detectable bacterium CFU. 
The detection was accurately set up and precisely optimised firstly through the usage of flat gold 
functionalised slides to be then translated to sinusoidal gold gratings for label-free GC-SPR detection using 
ellipsometer, in order to ensure a reproducible and precise identification of bacteria. Through azimuthally-
controlled GC-SPR, 10 CFU were detected, while in the case of fluorescence analysis results, a negative 
readout is obtained if incubating less than 104 CFU. Successful results were obtained when incubating 
environmental derived samples. This detection platform could be implemented as a prototype in which water 
and air samples will be sequentially concentrated, injected into a microfluidic system, and delivered to the 
SPR sensor for analysis. 
The peculiar Grating Coupled - Surface Plasmon Resonance method applied for this work has therefore 
revealed to be an accurate and highly sensitive strategy – with multiplexing possibility - for the sensing and 
detecting of different kind of biomolecules, from DNA fragments to whole bacteria cell. 
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Riassunto 
Il mio lavoro di Tesi di Dottorato, sviluppato presso i laboratori Veneto Nanotech (Nanofab a Marghera, 
LaNN a Padova ed ECSIN a Rovigo), ha avuto come obiettivo l’utilizzo della tecnologia di risonanza 
plasmonica di superficie (SPR – Surface Plasmon Resonance) per lo sviluppo di piattaforme biosensoristiche 
per applicazioni clinica ed ambientali. 
In particolare, durante il lavoro di Dottorato sono state messe a punto due piattaforme SPR: la prima 
piattaforma utilizza sonde oligonucleotidiche a DNA per l'individuazione di mutazioni causanti fibrosi 
cistica (CF) mentre la seconda utilizza anticorpi per il rilevamento di cellule di Legionella pneumophila. 
Entrambi i sensori sono basati sulla stessa strategia di rilevamento, ovvero l’utilizzo di una metodologia 
Grating Coupled – Surface Plasmon Resonance (GC-SPR) progettata utilizzando una configurazione conica 
di illuminazione ad azimut rotato per la rilevazione diretta – senza passaggi di marcatura, label-free – 
dell’analita in esame. 
Per quanto riguarda la piattaforma a DNA per la fibrosi cistica, si è sviluppata una strategia per 
l'individuazione di alcune delle mutazioni più frequenti responsabili CF tra la popolazione italiana. Per la 
rilevazione di tali mutazioni le superfici di analisi utilizzate sono grigliati sinusoidali, e la rilevazione 
specifica delle sequenze di interesse si ottiene attraverso l'utilizzo di oligonucleotidi allele-specifici (ASO – 
allele specific oligonucleotide) con struttura ad hairpin, disegnati per la discriminazione di un singolo 
nucleotide. I substrati plasmonici sono stati utilizzati per testare campioni wild-type ed eterozigoti (wt/mut) 
per le mutazioni in esame, amplificati tramite PCR a partire da campioni clinici. 
Le condizioni di ibridazione sono state ottimizzate per ottenere il rapporto di discriminazione (DR – 
discrimination ratio) massimo tra campioni wild-type ed eterozigoti. I segnali SPR ottenuti ibridando 
campioni wild-type e campioni eterozigoti hanno mostrato DR in grado di identificare univocamente i 
genotipi corretti, come confermato da esperimenti di fluorescenza in microarray eseguiti in parallelo. Inoltre 
la genotipizzazione ottenuta tramite SPR non è stata inficiata in campioni contenenti DNA interferente, 
consentendo quindi di utilizzare la piattaforma per la discriminazione in parallelo dei diversi alleli, e la 
possibilità futura di scalare il sistema con un approccio di high throughput screening. 
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Per quanto riguarda la piattaforma ad anticorpi per la rilevazione di Legionella pneumophila, la medesima 
strategia basata su GC-SPR è stata messa a punto per ottenere una rilevazione rapida e sensibile di tale 
patogeno. Il limite legale di L. pneumophila in ambienti ospedalieri ad alto rischio in Italia è di 102 UFC/L 
(unità formanti colonia) e la metodologia di riferimento per la sua identificazione è una tecnica di coltura 
microbiologica che richiede tempi di attesa fino a 7 giorni. 
Partendo da tali considerazioni un sistema GC-SPR altamente sensibile è stato sviluppato ed applicato per la 
rivelazione di L. pneumophila: la rivelazione è stata accuratamente impostata ed ottimizzata con un ceppo 
standard del battere, prima attraverso l'utilizzo di superfici d’oro non nanostrutturate (flat) opportunamente 
funzionalizzate ed analizzate tramite fluorescenza, e successivamente attraverso reticoli sinusoidali (grating) 
d’oro analizzati tramite elissometria GC-SPR. Attraverso la metodologia GC-SPR ad azimut rotato è stato 
possibile rilevare fino a 10 UFC, mentre con l’analisi in fluorescenza non è stato possibile identificare 
quantitativi di battere inferiori a 104 UFC. Risultati positivi sono stati ottenuti anche incubando campioni di 
L. pneumophila isolati direttamente dall’ambiente ospedaliero. 
Questa piattaforma di rilevazione potrà essere implementata come prototipo in cui campioni di acqua e aria 
potranno venir sequenzialmente concentrati, iniettati in un sistema di microfluidica, ed incubati sulla 
superficie del sensore SPR per l'analisi, obiettivi questi del progetto POSEIDON (Horizon2020) attualmente 
in corso. 
La particolare metodologia GC-SPR ad azimut rotato applicata in questo lavoro di Tesi si è dimostrata essere 
una strategia accurata e altamente sensibile - con possibilità di multiplexing - per la rilevazione di diversi tipi 
di biomolecole, a partire da frammenti di DNA fino ad intere cellule batteriche. 
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1. Introduction 
1.1 Sensors: overview and focus on optic biosensors 
In the last decades there has been an increasing interest in sensitive, specific and fast biosensors to address 
several societal and industrial needs. In particular, reliable and fast detection in the diagnosis field 
application as well as in the microbiological one is a key challenge in biosensing due to the strong impact 
on health. Standard molecular biology and microbiology-based methods can be highly efficient for this 
purpose, but at the same time can be very time consuming. In addition, most of these conventional methods 
require a biological facility, with specific instrument and trained personnel, thus they are not suitable for 
on-site or point of care analysis and cannot be carried out by untrained personnel. Therefore, new 
biosensing devices, capable of detecting analytes in a faster and equally accurate manner, are needed to 
help contributing to solve significant sensing challenges. 
According to IUPAC definition “A biosensor is a self-contained integrated device which is capable of 
providing specific quantitative or semi-quantitative analytical information using a biological recognition 
element (biochemical receptor) which is in direct spatial contact with a transducer element.”1 
A biosensor is a device composed of two elements (Figure 1): 
1. a bioreceptor that is an immobilized sensitive biological element (e.g. enzyme, DNA, antibody, etc..) 
recognising the analyte (e.g. enzyme substrate, complementary DNA, antigen, etc..). 
2. a transducer that is used to convert bio-chemical signal resulting from the interaction of the analyte 
with the bioreceptor into an electronic one. 
Biosensors can be grouped and classified according to different parameters, but classifying them according 
to their signal transduction way and working principle can be helpful, also if continuous technological 
novelty can modify and implement this classification: according to that, biosensors can generally be 
divided into three main types (Figure 2), namely: (1) electrochemical biosensors; (2) mass-based 
biosensors; and (3) optical-based biosensors. 
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Figure 1. General scheme of a biosensor: the biological part is either integrated or closely associated with 
the physical transducer, and behave as a recognition element, capable to detect a specific analyte. Once 
the interaction takes place, the bio-chemical signal generated will be converted by a physical transducer in 
a measurable discrete or continuous signal, whose intensity could be correlated to the analyte 
concentration. Picture from2. 
 
 
 
Figure 2. Biosensors classification according to the biorecognition element or to the transducing element: 
mass-based, electrochemical or optical biosensors. Picture from3. 
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Among these technologies, the optical one has reached a level of technological maturity that makes it a 
promising candidate for applications to specific sensing challenges.4 
Optical biosensors are those which can sense phenomena related to the interaction of the biorecognition 
element with the analyte and correlate the observed optical signal to the presence and concentration of 
target compounds, based on the measurement of photons involved in the process. More specifically, optical 
detection is based on the measurement of luminescence, fluorescence, colour changes, by the measurement 
of absorbance, reflectance or fluorescence emissions that occur in the ultraviolet (UV), visible, or near-
infrared (NIR) spectral regions.5 
Optical biosensors can be further classified as labelled-fluorescent biosensor, or label-free biosensors: the 
most crucial distinction between these techniques is that in label-free biosensors target molecules are not 
labelled or altered, and are detected in their natural forms, while in the labelled ones target molecules or 
biorecognition molecules need to be labelled with fluorescent tags, such as dyes, to ensure the 
biodetection. 
Both strategies are widely used in optical sensors construction6, with relative advantages and 
disadvantages: in this work the main optical label-free transduction strategy, i.e. surface plasmon 
resonance (SPR), will be exploited for biosensing application, using fluorescent microarray as reference 
technique. 
 
1.2 Surface plasmon resonance (SPR) 
1.2.1 Definitions and basic principles  
Among the most advanced sensing technologies currently explored for bioanalytes detection, the one 
exploited in this work is the label-free surface plasmon resonance technique. 
A surface plasmon (SP) is an electro-magnetic wave propagating along the surface of a metal-dielectric 
interface as charge density oscillations that may exist at the interface of two media with dielectric constants 
of opposite signs, for example air and a metal. Surface plasmons can couple with photons, creating the so-
called polariton, called in this case, surface plasmon polaritons (SPP).7–10 
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SPPs are localized in the direction perpendicular to the interface and will propagate along this interface 
until its energy is lost, with an exponential intensity decays (Figure 3). These features make SPPs 
extremely sensitive to optical and geometrical properties of the supporting interface, such as shape, 
roughness and refractive indices of the facing media.11 
 
 
 
Figure 3. Basics of surface plasmon polaritons, from12. a) SPP as a collective excitation at a metal–
dielectric interface. The electromagnetic field (electric field, E, plotted in the z–x plane; magnetic field, Hy, 
sketched in the y direction) is drastically enhanced. b) Field intensity is enhanced near the surface and 
decade exponentially with distance (δd for the dielectric and δm for the metal). 
 
SPPs can be excited by the photons of incident light at specific matching conditions, i.e. the momentum of 
incident photons must match the momentum of SPs, and the momentum matching results in resonance 
between SPs and incident photons. Thus, the energy carried by photons is transferred to SPs, which 
oscillate near the metal/dielectric interface. This resonance phenomenon is termed surface plasmon 
resonance. 
 
1.2.2 SPR interrogations 
A change in the refractive index of the dielectric – due for example to functionalisation, analyte binding, 
etc… – gives rise to a change in the propagation constant of the surface plasmon, which through the 
coupling condition alters the characteristics of the light wave coupled to the surface plasmon (e.g., 
coupling angle, coupling wavelength, intensity, phase). 
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On the basis of which characteristic of the light wave modulated by a surface plasmon is measured, SPR 
sensors are classified as sensors with angular (the most widely used), wavelength, intensity, or phase 
modulation.13
In SPR sensors with angular modulation, a monochromatic light wave is used to excite a surface plasmon. 
The strength of coupling between the incident wave and the surface plasmon is observed at multiple angles 
of incidence and the excitation of surface plasmons is observed as a dip in the angular spectrum of 
reflected light. 
In SPR sensors with wavelength modulation, a surface plasmon is excited by a collimated light wave 
containing multiple wavelengths and the excitation of surface plasmons is observed as a dip in the 
wavelength spectrum of reflected light. 
When a portion of the incident light energy is transferred to the SPP, as described before, with consequent 
absorption of light, it results in a reflectivity dip in the metal reflectivity spectrum at a certain resonance 
angle, θres1 (Figure 4, in blue). If refractive index changes at the metal/dielectric interface, for example 
after surface functionalisation or upon analyte binding to the bioreceptor, this results in a shift of the 
reflectivity dip to a different resonance angles θres2 (Figure 4, in yellow). 
Thus the presence of a new material at the metal/dielectric interface is detected from the resonance angle 
shift Δθres, without the need of labelling procedure, with all the advantages deriving from a label-free 
detection method. 
 
 
 
Figure 4. SPR causes an intensity dip in the reflected light at the sensor surface (θres1). The minimum of 
the dip can shift upon interaction occurring on the sensors surface (θres2), i.e. binding of the analyte. 
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1.2.3 SP excitation: Prism Coupled–SPR versus Grating Coupled–SPR and 
symmetry breaking in GC–SPR 
SPPs cannot be excited directly by a freely propagating beam of light incident upon the metal surface 
(Figure 5 A): coupling of photons into SPPs have to be achieved using a coupling medium to match the 
photon and SPP wave vectors, and thus match their momenta. In a dielectric k0 is increased and SPP can be 
excited since k0 can equal kSPP (Figure 5 B). 
 
 
A B 
 
Figure 5. A) The dispersion curve for a SP mode on air-gold interface shows the momentum mismatch 
problem that must be overcome in order to couple photon and SP modes together, with the SP mode (blue 
line) always lying beyond the photon line (black line) (kSPP > kph, air of the same frequency ω). B) SPP 
excitation can occur when kSP ≤ kph prism (red line), through the usage of a coupling medium, like a prism. 
 
The most common SPR based configuration is the one that adopts a prism to promote SPPs coupling with 
incident light (Kretschmann or prism coupling SPR – PC-SPR)8,15,16 like the one adopted by the well 
known Biacore® SPR instrument. Alternative configurations are available which are more suitable for 
instrumental miniaturization and multiplexing: unlike the most adopted Prism Coupled-SPR, that suffers 
from cumbersome optical alignment and bulky optics, GC-SPR configuration, where a metal layer is 
periodically patterned to couple incoming light with SPP modes, has shown indeed to be the most suitable 
solution for the miniaturization and integration of plasmonic platforms into nanodevices. PC-SPR and GC-
SPR basic configurations are depicted in Figure 6. 
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Figure 6. PC-SPR (left) and GC-SPR (right) basic configurations. SP: surface plasmon, θ:  incident light 
angle, ε0: prism dielectric constant, ε1: air dielectric constant, ε2: gold dielectric constant. 
 
GC-SPR configurations, however, are less sensitivity in terms of RIU (refractive index unit)17, but, 
nevertheless, their sensing performances can be improved by almost one order of magnitude by modifying 
the traditional SPR configurations to an azimuthally rotated GC-SPR (φ  0° GC-SPR).18 
As demonstrated recently19–22, the symmetry breaking of the plasmonic platforms provides advantages in 
sensing analyses: the azimuthal rotation allows metallic gratings to support the excitation of sensitivity-
enhanced surface plasmon polaritons with particular features, which are not present in the classical 
mounting. The sensitivity enhancement mechanism is attributed to the fact that the azimuthal orientation of 
the sinusoidal grating induces a double SPP excitation with a single incident wavelength. 
Due to the resulting symmetry breaking, polarization plays a fundamental role in SPP excitation, and it 
must be appropriately tuned in order to optimize the coupling strength. Indeed, by exploiting the degree of 
freedom given by the azimuthal rotation of the grating, a novel SPR architecture based on polarization-
modulation the incident light18,22–24 (Figure 7) will be used in the experiments illustrated in this Thesis. 
Beside a resolution competitive with commercial products, down to 10-7 RIU, polarization-based SPR 
provides a sensing mechanic that is simplified in comparison with other common architectures based on 
angular or wavelength interrogation. 
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Figure 7. Scheme of the experimental configuration geometry used for GC-SPR, adapted from22,25. The 
plasmonic substrate (period Λ = 500 nm and amplitude A = 40 nm) is mounted onto a rotating goniometer 
allowing the azimuthal control of the grating plane. In the azimuthal rotated configuration (φ ≠ 0°), the 
photon scattering plane is rotated by an angle φ with respect to the grating vector G (in green), so that 
when the coupling between the incident photon momentum (k(in)) and the surface plasmon polariton 
momentum occurs for a certain incident wavelength (λin) and angle (θin), a double reflectivity dip is 
registered, and sensitivities range from 500 to 800°/RIU (inset B). In the null azimuth configuration (φ = 
0°), a single reflectivity dip is registered, and sensitivities range from 50 to 150°/RIU (inset A). Light 
polarization could be tuned through a rotating polarizer (α is the polarization angle). Biological events on 
a surface are detected by the resonance angle shift (Δθres) derived from the reflectivity spectra. 
 
1.3 Microarrays and their applications in disease diagnostics 
The development of DNA microarray technology in mid 1990s allowed for the first time to simultaneously 
profile and study cell transcriptome and gene expression, exploiting the very same principle that makes 
nucleic acid so essential to information storage: hybridization to complementary sequences. 
Simply defined, a microarray is a collection of microscopic features (most commonly DNA, but also 
antibodies, peptides, etc…), which can be probed with target molecules to produce either quantitative (i.e. 
gene expression) or qualitative (i.e. diagnostic) data. Microarrays can be distinguished based upon 
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characteristics such as the nature of the probe, the solid-surface support used, and the specific method used 
for probe addressing and/or target detection. 
The “probe” refers to the DNA sequence bound to the solid-surface support in the microarray, whereas the 
“target” is the sequence of interest in the sample to be tested. 
In general terms, probes are synthesised and immobilised as discrete features, or spots. Each feature 
contains millions of identical probes. The target is fluorescently labelled and then hybridised to the 
microarray probes. A successful hybridisation event between the labelled target and the immobilized 
probes will result in an increase of fluorescence intensity over a background level, which can be measured 
using a fluorescent scanner26 (Figure 8). 
 
 
 
Figure 8. Classical steps for preparation and usage of a microarray for gene expression profiling. The 
targets for microarray analysis are two pools of fluorescently labelled cDNAs derived from mRNA of 
control (Cy3) and experiment (Cy5) cells. 
 
Although, historically, microarrays have been used largely for gene expression studies, this technology has 
gradually been applied in other field, including diagnostics. 
Several applications of DNA microarrays for diagnosing specific diseases have been reported and 
diagnostic microarrays have been used for genotyping and determination of disease-relevant genes or 
agents causing diseases, mutation analysis using relatively low-density DNA microarrays, screening of 
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single nucleotide polymorphisms (SNPs), detection of chromosome abnormalities like copy number 
changes at the level of chromosome using comparative genomic hybridization DNA microarrays (array 
CGH), global determination of post-translational modification, including methylation, acetylation, and 
alternative splicing27 (Figure 9). 
The performance of microarray-based diagnosis is continuously improving by the integration of other 
tools, and in this Thesis microarray technique has been used as reference when investigating SPR-based 
platforms performances for diagnostic application both in genetic disorder (oligo DNA-based platform) 
and infectious disease (antibody-based platform). 
 
 
 
Figure 9. Use of DNA microarrays for diseases diagnosis. Picture from27. 
 
The ideal microarray platform for a diagnostic laboratory is a low- to medium-density array that offers 
limited, reliable, and straightforward results without the need for sophisticated equipment and data 
management.28 
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2. Fabrication and sensing platform 
2.1 Reagents, solutions and instruments 
2.1.1 Reagents and solutions for molecular biology 
All the reagents and solution components used were purchased from Sigma-Aldrich (St. Louis, MO, USA), 
if not otherwise specified. The water used was of bidistilled (dd-H2O) or Milli-Q grade. Used solutions and 
buffers have the following composition: 
o Basic piranha solution: 5:1:1 dd-H2O, 30% H2O2 and 30% NH4OH 
o MES buffer for −COOH activation: 0.1 M 2-(N-morpholino) ethanesulfonic acid, 0.5 M NaCl, pH 
6.0 
o 20X SSC buffer: 3 M sodium chloride, 300 mM trisodium citrate, pH 7.0 
o 2X Oligo microarray printing buffer: 300 mM sodium phosphate, 0.02% Triton, pH 8.5 
o Oligo microarray blocking solution: 0.1 M Tris, 50 mM ethanolamine, pH 9 
o Oligo microarray washing solution: 4X SSC, 0.1% SDS 
o Protein microarray printing buffer: 0.1 M sodium phosphate, 0.3 M NaCl 0,01% Triton X100, pH 
7.2 
o Protein microarray blocking buffer: 50 mM sodium phosphate, 2.0% w/v Bovine Serum Albumin, 
pH 7.2 
o 10X Protein microarray washing solution: 0.5 M Tris, 2.5 M NaCl, 0.5% w/v Tween 20, pH 9.0 
o 10X PBS buffer: 1.37 M NaCl, 27 mM KCl, 100 mM Na2HPO4, 18 mM KH2PO4, pH 7.4. 
o 1X TBS/FBS buffer: 50 mM Tris-HCl, 150 mM NaCl, 0.05% FBS, pH 7.5 
 
2.1.2 Reagents for SPR gold surfaces fabrication 
The SPR sensing platforms were fabricated by combining laser interference lithography (LIL) performed 
at TASC-IOM-CNR laboratories (Basovizza, TS, Italy) and soft lithography techniques performed at 
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LaNN laboratories (Veneto Nanotech s.c.p.a., Padova). S1805 photoresist was purchased from Microposit 
(Shipley European Limited, UK), while MF319 Developer and PGMEA (propylene glycol monomethyl 
ether acetate) were purchased from MicroChem Corp (Newton, MA, USA). 
PDMS (polydimethylsiloxane; Sylgard 184) was purchased from Dow-Corning Corp. (Midland, MI, 
USA), and the thiolene resin, used for the lithographic master replica, NOA 61 (Norland Optical Adhesive) 
was purchased from Norland Products Inc. (Las Vegas, NV, USA). 
 
2.1.3 Instruments 
Below all the main instruments used for this Thesis are indicated: 
o Versarray Chipwriter Pro System (BioRad Laboratories, Hercules, CA, USA) 
o TeleChem SMP 2 Stealth Pins (Arrayit Corporation, Sunnyvale, CA, USA) 
o Microarray High-Speed Centrifuge (Arrayit Corporation, Sunnyvale, CA, USA) 
o Genepix 4000B laser scanner and Software (Molecular Devices, Sunnyvale, CA, USA) 
o NanoPhotometer Classic (Implen, Munich, Germany) 
o Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA) 
o Array Booster AB410 hybridization station (Advalytix, Munich, Germany) 
o Advawash Station AW400 (Advalytix, Munich, Germany) 
o Leica MicroSystems confocal microscope TCS SP5 II mounted on Leica DMI6000 CS (Wetzlar, 
Germany) 
o Tescan Vega II LMU scanning electron microscope (SEM) (VEGA TS 5130 LM, Tescan, Czech 
Republic) 
o VEECO D3100 Nanoscope IV atomic force microscope (AFM) (VEECO, Plainview, NY, USA) 
o Dual beam FEI Nova 600i scanning electron microscope (FEI, Hillsboro, OR, USA) 
o VASE ellipsometer (J.A. Woollam Co., Lincoln, NE, USA) 
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2.2 Fabrication 
2.2.1 Commercial slides (e-Surf LifeLine) 
Commercial e-Surf microarray slides (25x75 mm) were purchased from LifeLineLab (Pomezia, Italia). e-
Surf is an innovative, high performance activated substrate for protein and nucleic acid microarray 
applications, since it binds either amino-modified DNA or proteins via -NH2 groups and is therefore 
suitable for both oligonucleotides and proteins deposition. 
The proprietary functional 3D polymer is an innovative concept, offering many advantages over the 
traditional 2D sylanised glasses. The polymeric glass coating is obtained by physical adsorption of a N,N-
dimethylacrylamide (DMA), N,N-acryloyloxysuccinimide (NAS), and [3-(methacryloyl-
oxy)propyl]trimethoxysilyl (MAPS) copolymer. Each monomer confers to the copolymer a specific 
feature, in particular: 
• NAS: reactive group able to bind amino-modified DNA and primary amines of lysines and 
arginines in proteins. 
• DMA: forms the polymer backbone, facilitates polymer adsorption on the glass surface. 
• MAPS: covalently reacts with free silanols and stabilizes the coating. 
The 3D polymer ensures an optimal biomolecules orientation, allowing ligands to maintain their native 
configuration and to be available for subsequent binding.29 
 
2.2.2 Gold surfaces 
Flat and sinusoidal gold surfaces were kindly provided by Dr. Agnese Sonato and Dr. Gabriele Zacco, 
operating at TASC-IOM-CNR laboratories and at LaNN laboratories. 
The metal used for SPR surfaces must be capable of resonating with the incoming light at a suitable 
wavelength, in addition, the metal on the sensor surface must be free of oxides, sulphides and it must not 
react with other molecules on exposure to the atmosphere or liquid. Of the metals, gold is the most suitable 
choice, since it is very resistant to oxidation and other atmospheric contaminants but is compatible with 
many chemical modification systems. 
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The sensing surface consists of a thiolene resin sinusoidal grating (∼ 6 cm2) coated by a bi-metallic layer 
(Chromium (5 nm)/Gold (40 nm)) and supported onto a glass slide. Concerning plasmonic surfaces, the 
grating geometry was the following: period of 500 nm and amplitude of 40 nm. Surface fabrication process 
is illustrated in Figure 10 and summarised in the following steps and in Figure 10: 
1) Laser interference lithography (LIL) 
A S1805/PGMEA solution (2:3) was spun onto a silicon wafer with a spin speed of 6000 rpm for 30 s. The 
sample was exposed to a 50 mW helium cadmium (HeCd) laser emitting a TEM00 (Transverse 
electromagnetic) single mode at a 325 nm light source with a beam incidence angle of 19° and an exposure 
dose of 70 mJ/cm2. Resist developing was performed by immersing the samples in a MF319/Milli-Q water 
(10:1) solution for 15 s. Exposure and process parameters (i.e., beam incidence angle, exposure and 
developing time) were chosen in order to obtain a sinusoidal grating with a period of 500 nm and a peak-
to-valley amplitude of 40 nm. 
 
 
 
Figure 10. Fabrication strategy adopted for the realisation of the sensing substrates. Sinusoidal gratings 
were realised through laser interference lithography and replicated through soft lithography. Metal 
evaporation was finally performed onto the surface. 
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2) Soft lithography 
Soft lithography is a non-photolithographic technology based on self-assembly and replica molding for 
carrying out micro- and nanofabrication and it provides a convenient, effective, and low-cost method for 
the formation and manufacturing of micro- and nanostructures.  
For the replica of the prepared nanostructure, a PDMS mold was realised curing the PDMS layer dropped 
onto the resist grating at 60 °C for 4 h. The nanopattern was imprinted onto a thiolene resin film (NOA 61) 
supported onto a microscope glass slide, illuminating the PDMS mold with UV light (λ = 365 nm) for 30 s, 
using a standard metal halide 50 mW/cm2 lamp (DYMAX UV light flood lamp curing system, DYMAX, 
Torrington, CT, USA). A 12 hour thermal treatment at 50 °C was then performed in order to increase the 
resin adhesion onto the glass substrate. The final plasmonic substrate consisted of two identical gratings 
imprinted onto a microscope glass slide of 75 mm Å ~ 25 mm. 
3) Thermal evaporation 
A gold layer (40 nm) was evaporated above the patterned resin film and a thin chromium film (5 nm) was 
used as adhesion layer between the metal and the underlying dielectric medium. A VEECO D3100 
Nanoscope IV atomic force microscope (AFM) and a dual beam FEI Nova 600i scanning electron 
microscope were adopted to characterise the substrate topography and sinusoidal profile: results are 
reported in Figure 11: a period of 500 nm and a peak-to-valley amplitude of 40 nm were obtained. 
 
 
 
Figure 11. Surface topography SEM images of the sinusoidal plasmonic substrates realised in this work 
(a, b). The sinusoidal profile was collected by AFM measurements (c). 
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2.3 Substrates functionalisation
2.3.1 Gold substrates cleaning and SH-PEG-COOH functionalisation 
Thiolated PEG (polyethylene glycol) was used as antifouling layer to assure high surface protection from 
non-specific adsorptions: it is widely accepted that a hydrophilic polymeric layer should be inserted 
between the recognition element of the biosensor and the metal surface to prevent these interaction and to 
optimise sensing performances (Figure 12). Among all, PEG is one of the most effective agents used for 
this purpose, as demonstrated by wide literature evidences30–36, such that it has often been defined the “gold 
standard” of antifouling polymers, and its antifouling efficacy depends on the polymer chain length, its 
surface packing density and the fouling protein size.37,38 
 
 
 
Figure 12. (A) A sensing surface without an antifouling polymer coating is quickly coated in proteins when 
it comes into contact with samples (containing DNA, proteins, cells, etc…). (B) Passivating the surface 
with PEG or PEG derivatives reduces aspecific adsorption to the surface. Adapted from37. 
 
Although silver is known to have optimal plasmonic properties7, sensing substrates were fabricated with 
gold and PEG was anchored to the gold surface via self-assembly of thiol species onto the surface: gold 
binds thiols with high affinity (∼40-44 kcal/mol) and it does not undergo any undesired reactions with 
them, it is chemically stable and essentially inert, it does not oxide at temperature below its melting point 
(1064,18 °C), and it does not react with atmospheric oxygen neither with most chemicals.39–42 
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These properties make it possible to handle and manipulate gold samples under atmospheric conditions and 
allow the usage of liquid cleaning solutions containing for example oxygen peroxide, alcohol or 
ammonium.
In this work, gold substrates were preliminary cleaned through immersion into Basic Piranha solution for 
10 minutes at room temperature (RT) to avoid possible interference caused by organic residues: attention 
needs to be paid due to the corrosive nature of this solution. Substrates were then rinsed, dried under 
nitrogen flux, and kept in a clean and dry environment. 
A hetero bifunctional PEG (SH-PEG-COOH) was used to functionalise the surface, upon an incubation of 
24 hours in humidified environment of a 1mM aqueous solution. The molecule has a MW of 3.4 kDa 
(Laysan Bio, Arab, AL, USA) and its structure is depicted below in Figure 13. 
 
 
 
Figure 13. O-(3-Carboxypropyl)-O′-[2-(3-mercaptopropionylamino)ethyl]-polyethylene glycol (MW 3400 
Da). 
 
As can be seen, this molecule carries both a –SH group and a –COOH group: the approach consisted in the 
formation of a covalent bond between the –SH and the gold surface, and then obtain a –COOH 
functionalised surface that can be used for the subsequent activation and binding of -NH2 modified DNA 
probes or proteins trough a peptide bond. 
 
2.3.2 Evaluation of the –COOH functionalisation 
To verify the deposition of the –COOH layer obtained after SH-PEG-COOH incubation, the TBO 
(Toluidine Blue O) colorimetric quantitative assay can be performed. TBO test was performed on a 
representative number of nanostructured and not nanostructured gold PEGylated surfaces: the reagent 
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(Figure 14) is a cationic dye able to bind equimolar (1:1) to –COOH, trough electrostatic interactions, 
when it is in the deprotonated form (pH 10).43 
 
 
Figure 14. Toluidine Blue O (MW 305.83 Da). 
 
Changing pH from basic to acid (pH 2), the ionic interaction between the –COOH and TBO is lost causing 
the detachment of the dye from the surface ad its dispersion in solution. The amount of detached TBO can 
therefore be measured and correlated with the –COOH surface density. 
In particular, surfaces were immersed for 5 hours at 30°C in a TBO solution (5*10-4 M, pH 10). The 
solution was then removed and the surfaces were firstly washed with potassium hydroxide (NaOH 10-4 M, 
pH 10) to remove non-bounded dye, and then incubated with a known volume of acetic acid (CH3COOH 
50%, pH 2) to detach the interacting dye. 
TBO concentration was then determined measuring the solution optical density at λ = 633 nm - using 
Implen NanoPhotometer Classic. Through an appropriate calibration curve (obtained using TBO in 50% 
acetic acid solution, pH2) and normalising the results considering the sample surface area, it was possible 
to obtain the number of –COOH groups, and thus of HS-PEO-COOH molecules adsorbed onto the surface 
per cm2. 
The TBO test was performed on gold nanostructured gratings (n = 6) and the estimated density of carboxyl 
groups resulted to be in the order of 3*1015 -COOH/cm2 (±10%): this density appears to be sufficient for 
the anchoring of biomolecules and in accordance with the literature reported data.44 A theoretical 
estimation of appropriate surface biomolecules density was evaluated and reported: in particular, 
concerning antibodies – considering that the average molecular weight of an immunoglobulin is 170 kDa - 
and estimating that the average volume that will be used to fill a microwell (9mm*9mm - 81 mm2) will be 
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40 ul, with an antibody concentration of 1-0.5 mg/ml, the amount of antibody molecules/cm2 will be about 
3 orders of magnitude (1000 times) lower than the -COOH groups available on the surface and estimated 
by TBO assay, i.e. approximately 1012 molecules of antibody/cm2 vs 1015 -COOH groups/cm2. These 
indications are satisfactory for the effective biofunctionalisation of the substrates. 
 
2.3.3 Biomolecules coupling to activates surfaces trough microarray printing 
Concerning e-Surf microarray slides, amino-modified oligonucleotides or proteins can directly be bound to 
the surface, in the appropriate buffer, since these slides expose NAS, the reactive group that is able to bind 
amino modified DNA and primary amines of lysines and arginines in proteins. Concerning instead gold 
surfaces, after SH-PEG-COOH functionalisation, a preliminary activation needs to be performed to allow 
subsequent biomolecules coupling. 
 
2.3.3.1 EDC-mediated activation of –COOH functionalised gold surfaces 
Carbodiimide compounds provide the most popular and versatile method for labelling or crosslinking to 
carboxylic acids. The most readily available and commonly used carbodiimide for aqueous crosslinking is 
the water-soluble EDC. 
Carbodiimide conjugation works by activating –COOH for direct reaction with primary amines via amide 
bond formation. Because no portion of their chemical structure becomes part of the final bond between 
conjugated molecules, carbodiimides are considered zero-length carboxyl-to-amine crosslinkers. 
EDC crosslinking is most efficient in acidic conditions and must be performed in buffers devoid of 
extraneous carboxyls and amines. MES buffer pH 6 (4-morpholinoethanesulfonic acid) is a suitable 
carbodiimide reaction buffer. Phosphate buffers and neutral pH (up to 7.2) conditions are compatible with 
the reaction chemistry, albeit with lower efficiency; increasing the amount of EDC in a reaction solution 
can compensate for the reduced efficiency. 
N-hydroxysuccinimide (NHS) or its water-soluble analog (Sulfo-NHS) is often included in EDC coupling 
protocols to improve efficiency or create dry-stable (amine-reactive) intermediates. EDC couples NHS to 
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carboxyls, forming an NHS ester that is considerably more stable than the O-acylisourea intermediate 
while allowing for efficient conjugation to primary amines at physiologic pH (Figure 15). 
 
 
 
Figure 15. Sulfo-NHS plus EDC crosslinking reaction scheme. Carboxyl-to-amine crosslinking using the 
carbodiimide EDC and sulfo-NHS. Addition of NHS or Sulfo-NHS to EDC reactions (bottom-most 
pathway) increases reaction efficiency. 
 
For the experiments of this work, PEGylated gold surfaces were therefore incubated with a fresh prepared 
EDC-SNHS solution (in MES buffer, pH6) for 15 minutes at RT, to obtain a semi-stable amine-reactive 
NHS-ester. The activated surfaces were subsequently rinsed with Milli-Q water, N2 dried (or centrifuged 
with Microarray High-Speed Centrifuge) and immediately functionalised with the biomolecules of interest, 
in order to obtain a stable amine bond between -COOH and -NH2 groups. 
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2.3.3.2 Coupling of biomolecules to e-Surf microarray glass slides or gold 
activated slides 
Amino modified DNA probes or proteins were covalently bound directly to e-Surf microarray slides, or 
prior EDC-mediated activation to gold slides. 
In particular, amino-modified oligonucleotides were firstly resuspended at 100 μM concentration in Milli-
Q, then diluted in Oligo microarray Printing Buffer 1X to a final concentration of 20 μM, and finally 
deposited on the slide trough microarray spotter. Proteins/antibodies were instead diluted to the appropriate 
concentration (0,1-1 mg/ml) in Protein microarray print buffer 1X and finally deposited on the slide trough 
microarray spotter. 
The printing protocol was the same both for DNA oligo and for proteins and it is summarised below:  
1. Printing and coupling 
a) Print DNA solution/protein solution on activated slides to form microarrays 
b) Place printed slides in a slide storage box 
c) Set uncovered storage box in a saturated NaCl chamber. Over night incubation must be 
performed at an adequate humidity percentage: for this work, μBox with slideholders (Figure 16, 
QUANTIFOIL Instruments, Jena Germany) was used. 
d) Seal chamber and allow to incubate over night at room temperature. Store coupled slides at 
ambient condition until use. 
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Figure 16. The μBOX will protect the glass slides or micro well plates, as they are watertight, crushproof 
and have an automatic pressure purge valve. The μBOX is equipped with speed lock and will hold up to 2 
slideholders (each capable of holding up to 4 standard 75 x 25 mm slides). A moist sponge or paper towels 
soaked with a NaCl satured solution is placed in the bottom of the chamber to create a humid environment. 
 
The post-coupling processing was instead different, depending on the immobilised biomolecules, in 
particular: 
2a. Post-coupling processing for DNA oligonucleotides 
a) Place the slides in a slide rack and block residual reactive groups using pre-warmed 1X Oligo 
microarray blocking solution at 50°C for 15 minutes (extend to 30 minutes if not warm). 
b) Discard the blocking solution. 
c) Rinse the slides twice with water. 
d) Wash slide with Oligo microarray washing solution (pre-warmed to 50°C) for 15 to 60 minutes on 
the shaker. 
e) Discard wash solution and rinse the slides twice with water. 
2b. Post-coupling processing for proteins and antibodies 
a) Place the slides in a slide rack and block residual reactive groups using Protein microarray 
blocking buffer for 1 hour. 
b) Discard the blocking solution. 
c) Rinse the slides twice with 1X Protein microarray washing solution or 1X PBS solution. 
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The microarray deposition was performed by contact printing with TeleChem SMP 2 Stealth Pins (Figure 
17), using Versarray Chipwriter Pro System at controlled humidity condition (relative humidity 35%-45%) 
to properly control spot morphology and geometry. 
 
 
 
A B 
 
Figure 17. Microarray printing mechanism. A) Arrayit's printing technology (U.S. patent 6,101,946) 
enables high-speed manufacture of microarrays. The pins have flat tips and defined uptake channels, 
which allows a thin (25 um) layer of sample to form at the end of the pin, and printing to proceed by gentle 
surface contact. Printing occurs as a simple 3-step "ink-stamping" process as follows: (left) downstroke, 
(centre) contact, and (right) upstroke. B) VersArray ChipWriter Pro System. 
 
Printing scheme was designed to deposit geometrically defined blocks, to obtain 48 identical sub-arrays, 
organised in 4 columns and 12 lines. This will allow the subsequent hybridisation or incubation of up to 64 
different samples or replicas, using a specific mask, the ProPlate 64 slide chamber multi-wells (Figure 18, 
ProPlate, Sigma Aldrich), optimising experimental time, reagents consuming and avoiding replica-to-
replica variations. 
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Figure 18. Grace Bio-Labs ProPlate® microarray system, Wells dimension W × L 3.5 mm × 3.5 mm. 
 
2.3.4 Samples labelling and incubation 
Depending on sample nature and characteristics (DNA, proteins, cells, etc…), different labelling and 
incubation protocols were optimised and used. Details will be given in 3 and 4 specific Sections. 
 
2.3.5 Microarray fluorescent measurements 
Fluorescent measurements on hybridised arrays were performed using a Genepix 4000B laser scanner 
(Molecular Devices, Sunnyvale, CA) and the Gene Pix Pro software using both 532 and 635 nm 
wavelengths. Fluorescent spot intensities were quantified using the Gene Pix Pro software after 
normalising the data by subtracting local background from the recorded spot intensities. For each samples, 
five replicas were performed, each of them consisting in a subarray with a set of triplicate probes for each 
analysed mutation. 
 
2.3.6 Surface plasmon resonance measurements 
A J.A. Woollam Co. VASE ellipsometer with angular and wavelength spectroscopic resolution of 0.005° 
and 0.3 nm, respectively, was used for the reflectivity measurements on the SPR surface (Figure 19). A 
goniometer with a precision of 5’ mounted onto the sample holder allowed the sample azimuthal 
orientation control. Reflectivity measurements of the plasmonic gratings were performed in the dry state. 
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The setup consisted in a Xenon-Neon lamp (75W) as a light source with a monochromator and focusing 
system that allow selecting wavelengths in the range 270 − 2500 nm. Polarization state was controlled with 
a first polarizer and the output light that hits the sample was reflected into a detector arm, consisting in a 
rotating polarizer (analyser) and a photodiode system for signal conversion and amplification. 
 
 
 
Figure 19. VASE spectroscopic ellipsometer used in this work. (A) Optical bench for focusing and 
polarization control of the output light (monochromatised by a gating monochromator, located in sequence 
to a Xe-Neo 75 W lamp), (B) sample holder, (C) rotating goniometer for incidence angle scan, (D) 
detector. 
 
2.3.6.1 SPR interrogation parameters for DNA platform – angular interrogation 
Concerning DNA platform, for the rotated azimuth configuration, incident wavelength λ was set to 625 
nm, the azimuthal angle (φ) to 45°, and the incident light polarisation (α) to the value of 140° in order to 
optimize dip depth (α = 0° corresponds to transverse-magnetic - TM - polarisation). In the azimuthally 
rotated GC-SPR, in fact, TM polarisation is no longer the optimal one for SPP coupling, and the 
polarisation angle should be tuned according to the formula tan α = − tan φ cos θ, θ being the resonance 
polar angle.45 Incident angles range from 20° to 80° by a step of 0.2°. 
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Each surface was characterised before dressing procedures and after each functionalisation step. For each 
well, the analysis time required was 1 min per step. For each sample, two replicas were performed on each 
grating, and four replicas were therefore available in a single slide, composed by two gratings. 
 
2.3.6.2 SPR interrogation parameters for antibody platform – wavelenght 
interrogation 
Concerning antibody platform, for the rotated azimuth configuration incident wavelength λ ranged from 
600 to 800 nm, the azimuthal angle (φ) was set to 45° and the incident light polarisation (α) to the value of 
140° in order to optimize dip depth (α = 0° corresponds to transverse-magnetic - TM - polarisation). The 
incident angle was set to 70°. Each surface was characterised before dressing procedures and after each 
functionalisation step. 
The wavelength interrogation – and not the angular one – was used for antibody platform since, for 
biosafety reasons, a microfluidic cell was used to perform the experiment, as will be described in Section 
4. This device allowed the usage of single incident angle (70°) therefore SPR measurements were 
performed through wavelength interrogation. 
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3. DNA platform for Cystic Fibrosis 
causing mutations detection 
In this Section, a strategy for the investigation of some of the most frequent mutations responsible for 
cystic fibrosis (CF) among the Italian population is described. For the detection of the CF mutations, a 
highly sensitive Grating Coupled−Surface Plasmon Resonance enhanced spectroscopy method for label-
free molecular identification was applied, exploiting a conical illumination configuration. Gold sinusoidal 
gratings were used as sensing surfaces, and the specific biodetection was achieved through the coupling 
with DNA hairpin probes designed for single nucleotide discrimination. Such substrates were used to test 
unlabeled PCR amplified homozygous wild type (wt) and heterozygous samples, deriving from clinical 
samples, for the screened mutations. 
Hybridisation conditions were optimised to obtain the maximum discrimination ratio (DR) between the 
homozygous wild type and the heterozygous samples. SPR signals obtained from hybridising wild type 
and heterozygous samples showed DRs able to identify univocally the correct genotypes, as confirmed by 
fluorescence microarray experiments run in parallel. Furthermore, SPR genotyping was not impaired in 
samples containing unrelated DNA, allowing the platform to be used for the concomitant discrimination of 
several alleles also scalable for a high throughput screening setting. 
 
3.1 Introduction 
3.1.1 Cystic fibrosis disease 
Cystic fibrosis (CF) is one of the most common lifeshortening inherited diseases among the Caucasian 
population, as its incidence is 1 in 2000− 2500 live births. CF, inherited in a Mendelian autosomal 
recessive way, is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) 
gene. The gene was identified in 198946,47, located on the long arm of chromosome number 7 (band q31) 
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and coding for a chlorine ion channel protein48,49, a 1480 amino acid membrane bound glycoprotein with a 
molecular mass of 170,000 Da (Figure 20). 
An abnormal CFTR protein results in defective electrolyte transport and defective chloride ion transport in 
the apical membrane epithelial cells of the sweat gland, airway, pancreas, and intestine. 
As recessive diseases, CF presents “ carrier” individuals: these are genetically heterozygous for a specific 
mutation on CFTR gene, i.e. only one of the two CTFR alleles carries the mutation (wild type/mutant 
alleles: wt/mut). Heterozygotes are phenotypically normal, as healthy as individuals with both wild type 
alleles (wild type/wild type alleles: wt/wt), defined as wt homozygous. When a particular mutation is 
instead present on both alleles of the CFTR gene, a mut homozygous condition is recognised 
(mutant/mutant alleles: mut/mut), and individuals with this genetic profile are phenotypically affected by 
CF disease. 
 
 
 
Figure 20. CFTR has been proposed to have two transmembrane (TM) domains (TM1 and TM2) (in green 
and grey) predicted to contain six hydrophobic membrane-spanning regions, two nucleotide-binding (NB) 
domains (NBD1 and NBD2) (in red) and one regulatory (R) domain (in blue). R domain contains several 
potential sites for phosphorylation by cAMP dependent PKA or PKC. The activity of CFTR as an ion 
channel depends upon phosphorylation of the R domain and binding of ATP to the nuclear binding 
domains. Figure adapted from47. 
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Almost 1000 different mutations have been identified in the CFTR gene, however, the vast majority of 
them are at frequencies lower than 0.1%. Mutations of the CFTR gene can be classified into five classes 
according to the mechanism by which they disrupt the synthesis, traffic and function of CFTR protein.50 
Class I and II represent approximately 12% and 87% of the CFTR mutations that cause CF in patients 
worldwide, respectively, while class III, IV and V represent 5% each (Figure 21). 
 
 
Figure 21. Classification of CFTR mutations. Figure adapted from51. 
 
The most frequent mutation, ΔF508, accounts for 30% − 88% of CF chromosomes worldwide (Figure 22), 
depending upon race/ethnicity. This mutation consists in a deletion of the three nucleotides that comprise 
the codon for phenylalanine (F) at position 508. Among the Italian population, ΔF508 has a frequency in 
carriers of more than 40%, followed by two other mutations with a frequency in carriers of 5 − 6% each: 
R1162X and N1303K.52,53 
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Figure 22. Most common CFTR mutations around the world: birth prevalence is reported as number of 
live births per case of CF. Common/important mutations in each region are listed below the prevalence. 
Adapted from54.  
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3.1.2 Cystic fibrosis genotyping 
CF genotyping has seen rapid and efficient growth in recent years since, more than the most commonly 
used CF diagnostic techniques, novel assays and methods might be employed to enhance the detection 
throughput performances. The most widely traditional used techniques to diagnose CF are ASO (allele-
specific oligonucleotide) dot-blot, based upon hybridisation of a labelled oligonucleotide probe with the 
target DNA anchored to a membrane, and reverse dot-blot, in which oligonucleotide probes are bound to 
the membrane on which the biotinylated amplified target DNA is hybridised.55–58 Other detection 
techniques based on nucleic acid specific amplification and identification include amplification refractory 
mutation system (ARMS) or allele specific amplification59,60, oligoligation assay (OLA)61, polyacrylamide 
gel electrophoresis (PAGE) separation of the heteroduplexes62, single-stranded conformation 
polymorphism (SSCP)63,64, and denaturing gradient gel electrophoresis (DGGE).65 
More recently, biosensor-based techniques for the detection of CF mutation were reported, as 
electrochemical biosensors based on methylene blue-DNA interaction66, DNA microarrays67–71, or 
biospecific interaction analysis (BIA) monitored through surface plasmon resonance based technology72–77, 
performed both through the usage of DNA and PNA molecules.78,79 
SPR is a promising high-sensitivity, fast, and low cost technique that meets the requirements for the 
development of reliable accurate methods in the detection of CF mutations. Most of the literature results 
based on the SPR technique are performed using the prism-coupling detection method (PC-SPR) and 
synthetic complementary oligonucleotides as target DNA: in these works limited evidence is available 
assessing the performances of SPR-based biosensors on clinical samples. Typically, in these studies, a 
single mutation is analysed at a time, to discriminate between homozygous and heterozygous states, e.g. in 
CFTR74,75,77, in BRCA180, or in p53 gene.81 
 
3.1.3 Aim of the study 
The present study is focused on the development of a DNA azimuthally rotated grating-coupled surface 
plasmon resonance-based sensor21 for the detection of some of the most common CFTR related mutations. 
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GC-SPR under azimuthal control, as demonstrated in its first application in simple chemical systems21,22, 
gives the possibility to enhance the SPR detection sensitivity up to 1 order of magnitude (up to 600 and 
800°/RIU) with respect to standard GC- and PC-SPR methods (typically 50−150°/RIU).82 In addition, 
more SPPs can be supported with the same illuminating wavelength. On top of that, through symmetry 
breaking after grating rotation, polarization assumes a fundamental role on surface plasmon polaritons 
excitation, and it must be properly tuned in order to optimize the coupling strength. 
Allele specific oligonucleotide stem-loop probes have been designed to achieve precise CF genotyping due 
to the presence of a hairpin-forming region. In the presence of a full complementary DNA, the probe loses 
its closed structure, allowing the formation of a stable hybrid, while in the presence of mismatched or non-
complementary DNA it maintains its secondary structure.83,84 
Clinical PCR amplified samples - derived both from homozygous wild type (wt/wt) and clinical 
heterozygous samples (wt/mut) - were used to set up the SPR system, and results were compared also to 
fluorescent-based microarray experiments in terms of genotyping ability and discrimination power. 
Experiments were also performed using PCR amplified samples mixed with fragmented human genomic 
DNA as an interferent to verify the efficacy of the detection performances of the SPR sensor. These results 
successfully proved the reliability of the SPR platform in discriminating between the presence of a wild 
type or mutant allele in the samples.  
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3.2  Materials and Methods 
3.2.1 Primers and Allele Specific Oligonucleotide DNA probes design 
The three most frequent mutations among the Italian population of the CFTR gene were selected (Δ F508, 
R1162X, N1303K), and their localization was verified through the CFTR mutation database 
(http://www.genet.sickkids.on.ca/app). For each mutation, a pair of primers able to amplify the genomic 
portion of interest through PCR was selected (Table 3). Selected primers were purchased from IDT 
Integrated DNA Technologies (Leuven, Belgium). 
Based on the genomic regions identified by the relative primers, specific wild type (wt) and mutant (mut) 
probes for DNA microarrays were selected, using Array Designer software (Premier Biosoft, CA, USA). 
Selected probes were also checked for their specificity through the Basic Local Alignment Search Tool 
(BLAST). For the complete ASO probe design, a portion of each hairpin was defined with a length of six 
base pairs. The stability of the secondary structure was examined in order to standardize the Tm and ΔG of 
the hairpin region of all the created structures. Results obtained for the hairpin selected portions and for the 
final probes are summarised in Table 4. Probes were purchased from IDT Integrated DNA Technologies 
with a 5′ C6-NH2 modification, to allow subsequent surface functionalisation. 
Hybridisation conditions for the CFTR microarray were first set up through the preliminary usage of 
complementary fluorescent (Cy3 and Cy5) oligonucleotides (HPLC purified), purchased from IDT. 
 
3.2.2 Surface functionalisation 
Commercial microarray glass slides and gold slides were functionalised as described in Section 2. 
Concerning gold substrates, probes were anchored through ECD-mediated coupling with the usage of a 
ProPlate 64 slide chamber multiwells: up to 16 wells of 3.5 mm × 3.5 mm are obtained for each grating. 
Each well was functionalised with a single specific probe, leaving two empty cells per grating as 
measurement references: an example of plasmonic surface organization is showed in Figure 23: up to 14 
samples can be tested per grating, and up to 28 per slide. 
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    Grating 1    Grating 2 
              
              
              
              
 
Figure 23. Example of SPR surface scheme created on a microscope glass slide (75mm x 25mm), with 2 
gratings having 16 wells each. Flat gold wells (light pink) divide the two gratings, in which reference cells 
(2 per grating) are highlighted in orange and test cells (14 per grating) are in light orange. 
 
Concerning instead commercial microarray slides, in a single slide up to 48 subarrays were printed; six 
replicas of alignment probes were spotted, plus three replicas of each investigated wt or mut probe, to 
ensure proper statistical analysis: the resulting scheme is depicted in Figure 24. 
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Figure 24. A) Deposition scheme of each of the 48 subarrays adopted for microarray printing on e-surf 
LifeLine slides. V = empty spots, B = buffer, AL = alignment spots. 10W = ΔF508 wt probe; 10M = ΔF508 
mut probe; 19W = R1162X wt probe; 19M = R1162X mut probe; 21W = N1303K wt probe; 21M = 
N1303K mut probe. B) Scheme of a complete slide, including 48 identical subarrays. 
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3.2.3 Samples preparation and hybridisation 
Human DNA extracts were kindly provided by Dr. L. Picci (Pediatric Department, Padua Hospital, 
University of Padova). In particular, a homozygous wild type (wt/wt alleles) and a heterozygous (wt/mut 
alleles) sample for each of the three analysed mutations were obtained after verification through DNA 
sequencing. No homozygous mutant samples were available. 
DNA samples were PCR amplified using AmpliTaq Gold 360 DNA polymerase reagents (Applied 
Biosystem, Life Technologies, Milan, Italy). 
Reagents concentration and PCR amplification conditions are illustrated below (Table 1): 
 
Table 1 PCR reagents concentration (left) and amplification conditions (right). 
 
Components Final concentration 
DNA template Variable 
25 uM Forward Primer 0,5 uM 
25 uM Reverse Primer 0,5 uM 
10X PCR Buffer 1X 
25 mM MgCl2 1,5 mM 
10 mM dNTPs 200 uM 
Taq Polymerase (5 U/μl) 2,5 U 
Milli-Q H2O to volume 
 
Thermocycling conditions 
Step Temperature Time 
Initial Denaturation 95 °C 5 min 
Amplification 
40 Cycles 
95 °C (denaturation) 
50 °C (amplification) 
72 °C (extension) 
30 sec 
30 sec 
1 min 
Final Extension 72 °C 7 min 
Hold 4 °C  
 
 
PCR products were purified with silica spin columns (PureLink PCR Purification Kit, Life Technologies) 
and analysed through an electrophoretic run on an Agilent Bioanalyzer with a DNA chip (Figure 25). 
Fluorescent PCR products were obtained using a mix of dCTP-Cy3 or dCTP-Cy5, for wild type or 
heterozygous samples, respectively (GE Healthcare, Little Chalfont, UK). Fluorophore incorporation was 
verified spectrophotometrically. 
Human genome from the lymphoma cell line (BL41 cell line, LGC standards, UK) was extracted with 
QIAamp DNA Mini Kit (Qiagen, Hilden, Germany) and fragmented with double strand DNA Fragmentase 
using the conditions indicated by the supplier (New England Biolabs, Ipswich, MA, USA). Obtained 
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fragments ranged from 300 bp to 600 bp, as verified by capillary gel electrophoresis with the Agilent 
Bioanalyzer, and were used as interferent DNA in the subsequent preparations. 
 
 
 
Figure 25. Agilent 2100 Bioanalyzer workstation. 
 
CFTR PCR fragments, Cy3/Cy5-labeled or unlabeled, were incubated on e-surf microarray slides and on 
gold plasmonic slides, respectively. Mixtures were denatured, cooled, and hybridised for 3 h at 37 °C, in an 
optimised hybridisation buffer (2X SSC, 0.1% SDS, 0.2 mg/mL Bovine Serum Albumin, 20% formamide), 
in the Array Booster AB410 hybridisation station (Figure 26 A). ProPlate 64 multiwells slide chambers 
were used to physically isolate each subarray during incubation with different samples. 
For fluorescent analysis, one PCR sample could be simultaneously tested for the mutation of interest in the 
whole subarray that included the six specific probes (three wild type and three mutants, each in triplicate, 
see Figure 24). 
For SPR experiments, instead, each PCR product obtained for all of the three loci was split into two wells 
to analyse separately sample hybridisation on the wild type or on the mutant probe anchored on different 
wells on the sensing surface. 
After hybridisation, slides were washed in the Advawash Station AW400 (Figure 26 B) for 5 min in 1X 
SSC 0.1% SDS at 37 °C, 2 min in 0.2X SSC at RT, 2 min in 0.1X SSC at RT and 30 s in Milli-Q H2O at 
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RT, spin-dried using Microarray High-Speed Centrifuge and submitted to SPR analysis or scanned for 
fluorescent emission. 
 
  
A B 
 
Figure 26. A) Array Booster AB410 hybridisation station and B) Advawash Station AW400. 
 
3.2.4 SPR and fluorescence measurements 
SPR and fluorescence measurements were performed as described in Section 2. In particular, concerning 
SPR measurements, substrates were characterised after each experimental step with the parameters of 
Table 2: 
 
Table 2. Characterisation parameters used for SPR measurements. 
 
Incident wavelength [nm] 625 
Light incidence angle [°] 32-46 
Azimuth [°] 45° 
Polarization [°] 140° 
 
Reflectivity measurements were carried out in the following steps: 
 after piranha cleaning; 
 after PEG functionalization; 
 after probe anchoring; 
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 after target hybridization 
The described procedure allowed to control all the experimental steps with high precision and accuracy in 
order to be able to reproduce the optimised experimental conditions. 
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3.3 Results and Discussion 
3.3.1 Primers and Allele Specific Oligonucleotide DNA probes design 
For each of the 3 mutations to be analysed, a pair of primers able to amplify the genomic portion of interest 
through PCR was selected (Table 3). 
 
Table 3. PCR primers for CFTR genomic regions’ amplification.a 
 
Name Sequence 5’-3’ nt GC% Tm °C 
Amplicon length 
(wt/mut) 
ΔF508 (ex10) F ATGATGGGTTTTATTTCCAGAC 22 36.4 50.9 
271/268 
ΔF508 (ex10) R ATTGGGTAGTGTGAAGGGTTC 21 47.6 54.6 
R1162X (ex19) F GCCCGACAAATAACCAAGTGA 21 47.6 55.5 
454/454 
R1162X (ex19) R GCTAACACATTGCTTCAGGCT 21 47.6 55.8 
N1303K (ex21) F AATGTTCACAAGGGACTCCA 20 45.0 53.9 
473/473 
N1303K (ex21) R CAAAAGTACCTGTTGCTCCA 20 45.0 52.9 
 
aPrimer sequences were adapted from sequences reported by85. nt: nucleotide length. GC%: guanine-
cytosine percentage. wt: wild type DNA. mut: mutant DNA. 
 
Concerning microarray probes, hairpin-shaped molecule were designed to discriminate between wild type 
and mutant sequences: they consisted of a probe sequence embedded between complementary sequences 
that form a hairpin stem, attached to the microarray surface by only one of its strands. In the absence of an 
amplified DNA (target), probe is held in the closed state, while when the target binds perfectly to its probe 
(no mismatch), the greater stability of the probe-target helix forces the stem to unwind, resulting in an 
opening of the probe, permitting hybridisation (Figure 27). 
It would be therefore possible to increase specificity differentiating between two DNA targets that differ 
by as little as a single nucleotide.86–88 
According to literature’s information, a length of 18−22 nucleotides was chosen as optimal for probes’ 
design, to discriminate single base mutations with high accuracy. It should be noted that the probes’ design 
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was highly constrained by the position of the mutation itself, which should be placed in the central position 
of the probe, in order to maximize mutation discrimination capability89,90, and by the nucleotide 
composition of the sequence surrounding the mutation itself.
 
 
 
Figure 27. Cartoon depicting the hybridisation mechanism of ASO hairpin probes for the discrimination of 
single nucleotide mutations. 
 
The portion of each hairpin probe was designed as indicated in literature regarding the length of the portion 
and a length of 6 bp is set55,56, carefully evaluating the stability of the structure in order to standardize the 
Tm and ΔG of the hairpin regions. For the ASO probes, design results are summarised in Table 4: the 
hairpin portion is indicated in bold and underlined; probes with the hairpin portion show excellent 
uniformity in chemical−physical characteristics, especially concerning the average Tm. The hairpin regions 
with stem-loop motif were designed in order to obtain a narrow range of melting temperature for all of the 
probes, as well as for the stem region, and comparable structure and ΔG. 
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Table 4. Sequences of Microarray ASO Probes.b 
 
Name Sequence 5’-3’ Structure Nt Tm °C GC% 
ΔG hairpin 
portion 
kcal/mol 
Tm 
hairpin 
portion °C 
ΔH hairpin 
portion 
kcal/mol 
ΔS hairpin 
portion 
kcal/mol 
ΔF508 
CAATCGAAT
ATCATCTTT
GGTGTTTCC
TCGATTG 
 
34 59,2 38,2 -3,2 44,7 -51,5 -162,02 
ΔF508 mut 
CAATCGATA
TCATTGGTG
TTTCCTATG
TCGATTG 
 
34 59,0 38,2 -4,87 43,6 -83 -262,07 
R1162X 
CCATCATCT
GTGAGCCGA
GTCTTTTGA
TGG 
 
30 62,1 50,0 -2,24 41,5 -42,8 -136,02 
R1162X mut 
CCATCAATC
TGTGAGCTG
AGTCTTTAT
GATGG 
 
32 60,1 43,8 -2,47 42,9 -43,6 -137,96 
N1303K 
CAAGCATTT
AGAAAAAAC
TTGGATCCC
TTGCTTG 
 
34 60,2 38,2 -2,52 42,7 -44,9 -142,15 
N1303K mut 
CAAGCATTT
AGAAAAAA
GTTGGATCC
CTTGCTTG 
  
34 60,2 38,2 -2,52 42,7 -44,9 -142,15 
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bThe hairpin region with the mutated oligonucleotides is represented in red, and the hairpin portion is bold 
and underlined. Thermodynamic analysis was performed using IDT DNA software 
(http://eu.idtdna.com/analyzer/applications/oligoanalyzer/), evaluating with software default parameters 
(oligo concentration = 0.25 μM, Na+ concentration = 50 mM) the whole probe sequence and the hairpin 
structure (T = 25 °C, Na+ concentration = 25 mM, suboptimality = 50%). 
 
3.3.2 Hybridisation conditions setup and optimization through fluorescent 
analysis 
Hybridisation conditions for the CFTR microarray were first set up through the preliminary usage of 
complementary fluorescent (Cy3 and Cy5) oligonucleotides (Table 5). These perfect match oligos were 
used to preliminary test the ability of the deposited ASO probes to recognize specifically the wt or mut 
sequence, and potentially to correctly genotype the subsequent samples. 
 
Table 5. Oligonucleotide sequences of DNA fluorescent (Cy3 or Cy5) complementary targets. 
 
Name Sequence 5’-3’ 
ΔF508 Cy3/AGGAAACACCAAAGATGATATT 
ΔF508 mut Cy5/CATAGGAAACACCAATGATAT 
R1162X Cy3/AAAGACTCGGCTCACAGA 
R1162X mut Cy5/TAAAGACTCAGCTCACAGAT 
N1303K Cy3/AGGGATCCAAGTTTTTTCTAAA 
N1303K mut Cy5/AGGGATCCAACTTTTTTCTAAA 
 
The performances of the chosen hybridisation setting were subsequently confirmed using fluorescently 
labelled PCR products deriving from clinical samples to analyse the screening potential of the platform. 
Several conditions were deeply investigated, applying variations to SSC and formamide concentrations and 
to hybridisation temperature to achieve optimal genotypisation. 
Conditions were optimised for oligos hybridisation, considering the contribution to the Tm given by 
monovalent cations concentration (Na+), formamide percentage, probe length and GC%. Tm was calculated 
using the following formula for DNA:DNA hybrids:91 
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Tm = 81,5 + 16,6*log (Na+ Molarity) + 0,41*GC% - 0,72*formamide% - 500/oligo length 
 
Hybridisation temperature (Thyb) was calculated to obtain a Δ between Tm and Thyb of 20-25°C (moderate 
stringency) or between 15-20°C (high stringency). 
Buffer composition was set to operate with an hybridisation temperature ranging from 25°C to 37°C (range 
temperature lower than theoretical melting temperature of the hairpin probes) in order to ensure hairpin’s 
probe structure maintenance, and thus the possibility to obtain a theoretical optimal discrimination between 
perfect match and mismatch, and at the same time to operate with a possible portable device at or above 
room temperature. 
Some of the most promising oligos hybridisation settings were tested on PCR amplified clinical samples, 
fluorescently labelled with Cy3 or Cy5 d-CTP. The hybridisation protocol that allowed detecting the 
proper allele with the higher specificity included a buffer composition with SSC 2X and formamide 20%, 
at a hybridisation temperature of 37 °C. Fluorescence microarray hybridisation results were collected, and 
the ratio between the signal on the mutated probe and the one on the wild type probe was calculated, 
obtaining the discrimination ratios (DR) for each analysed locus, as shown in Figure 28. These ratios 
indicate the ability to discriminate between a perfect and a mismatched target sequence and are necessary 
to establish a univocal way to genotype unknown samples. 
For wt samples (wt/wt), DRs more close to zero are expected for an optimal genotypisation indicating that 
the wt DNA is almost completely hybridised on the wt probe. Reported DRs demonstrate that, for all the 
wt tested samples, obtained values were suitable for genotyping. In particular, for wt ΔF508 and wt 
R1162X, all reported values are included between 0.01 and 0.08. 
Regarding the N1303K wt sample, the obtained DR is 0.4, relatively higher if compared to the DR rates 
obtained for the other wt samples, but still able to genotype correctly the sequence. This can be attributed 
to the chemico-physical characteristics of N1303K wt and mut probe couple, constrained by the mutation 
position itself, and by the surrounding nucleotides. 
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ΔF508 wt Cy3 R1162X wt Cy3 N1303K wt Cy3 
 
DR mut/wt=0.03 
 
DR mut/wt=0.08 
 
DR mut/wt=0.4 
ΔF508 hetero Cy5 R1162X hetero Cy5 N1303K hetero Cy5 
 
DR mut/wt=0.9 
 
DR mut/wt=0.9 
 
DR mut/wt=1.3 
 
Figure 28. Microarray hybridization results obtained with PCR fragments, labelled with Cy3 (green, wt 
samples) or with Cy5 (red, heterozygous samples) under the optimised hybridization conditions (SSC2X, 
formamide 20%, hybridization temperature 37 °C 3h). Results are shown both as images and numerically 
as discrimination ratios (DR). Yellow boxes: include wt and mut probe for the analysed mutation. wt: wild 
type samples. hetero: heterozygous samples. 
 
For heterozygous samples (wt/mut), DRs more close to 1 are expected for an optimal genotypisation, 
indicating that the heterozygous sample is equally hybridised on the two probes (wt and mut). Concerning 
heterozygous samples, for all the tested samples, DRs between 0.9 and 1.3 were achieved: obtained DRs 
are in line with the expected DR value and are particularly suitable to achieve a precise genotyping of the 
heterozygous samples. 
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3.3.3 SPR response to PCR amplified clinical samples 
Hybridisation of CFTR unlabeled PCR products was performed on plasmonic slides, with the same 
condition used and optimised for fluorescent readout. Results are numerically expressed in Table 6 and 
representative graphs are shown in Figure 29. 
Experiments were performed always in parallel with hybridisation on microarray of labelled PCR, as 
control. Shifts were collected after substrate cleaning, surface biofunctionalisation, and sample incubation. 
 
Table 6. SPR shifts obtained after hybridisation of CFTR related PCR products.a 
 
 
Screened Mutation 
ΔF508 R1162X N1303K 
PCR 
hybridised on 
wt PCR hetero PCR wt PCR hetero PCR wt PCR hetero PCR 
wt probe 0.64° ± 0.06° 0.26° ± 0.06° 0.51° ± 0.06° 0.24° ± 0.07° 0.45° ± 0.07° 0.31° ± 0.08° 
mut probe 0.13° ± 0.06° 0.19° ± 0.07° 0.05° ± 0.06° 0.77° ± 0.07° 0.08° ± 0.06° 0.38° ± 0.06° 
DR rangeb 0.1–0.2 0.7–3 0.1–0.2 0.7–3 0.1–0.2 0.9–2 
 
aEach sample is incubated both on wt and on mut related probe. Values of the shifts are representative of 
one experiment. bDRs are mediated on results of three independent experiments.  
 
ΔF508 wt PCR sample 
on wt probe 
 
on mut probe 
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ΔF508 heterozygous PCR sample  
on wt probe 
 
on mut probe 
R1162X wt PCR sample  
on wt probe 
 
on mut probe 
R1162X heterozygous PCR sample 
on wt probe 
 
 
on mut probe 
 
  
 
61 
 
N1303K wt PCR sample 
on wt probe 
 
on mut probe 
N1303K heterozygous PCR 
on wt probe 
 
on mut probe 
 
Figure 29. SPR shifts obtained after hybridisation of CFTR related PCR products. Reflectivity curves were 
collected for the bare grating after substrate cleaning (black dots), after SH-PEG-COOH plus -NH2 
modified probe immobilization on the surface (blue line), and after sample incubation (red line). Three 
measurements per point were performed. The curves were fitted using a Lorentz function; the error was 
propagated and then mediated on all the measurements. The reflectivity minimum was derived from the 
fitting procedure. 
 
For tested wt samples, a significant shift was recorded after incubation of the sample on the related wt 
probe (0.45°−0.64°), while no significant signal, i.e., a signal comparable to the measurement error (up to 
0.15°), was detected on the mut one (0.05°−0.13°). 
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In the case of heterozygous samples, resonance angle shifts were collected on both relative probes 
(0.19°−0.77°). DRs for wild type and heterozygous samples were calculated from the shift ratios. 
In the case of wt samples DR is included between 0.1 and 0.2 for all the tested samples, underlining 
genotyping ability of all wt probes in the SPR configuration. Concerning mut probes DR ranges from 0.7 
to 3, underlying that also in this case precise genotypisation can be achieved. 
 
3.3.4 SPR response in presence of interferent DNA 
A series of experiments were performed to verify the system genotyping ability in presence of a more 
complex sample, resembling the ones routinely used for molecular CF detection, i.e. samples containing 
several PCR amplified CF related sequences. For this purpose, complex samples containing the target 
sequences and fragmented human genomic DNA were used. As shown in Table 7, the presence of 
interferent DNA did not mislead the genotypisation of the unknown samples. 
 
Table 7. Hybridisation shift obtained incubating the target PCR amplicons alone or mixed with interferent 
unrelated genomic DNA sequences.a 
 
Target wt/wt DNA 
 ΔF508 R1162X N1303K 
Probe 
 
 
Interferent b 
wt mut DR wt mut DR wt mut DR 
without 
0.56° ± 
0.08° 
0.13° ± 
0.06° 
0.23 ± 
0.11 
0.45° ± 
0.06° 
0.11° ± 
0.07° 
0.24 ± 
0.16 
0.45° ± 
0.07° 
0.08° ± 
0.06° 
0.18 ± 
 0.14 
with 
0.70° ± 
0.07° 
0.07° ± 
0.06° 
0.10 ± 
0.09 
0.53° ± 
0.06° 
0.04° ± 
0.08° 
0.08 ± 
 0.15 
0.45° ± 
0.07° 
0.12° ± 
0.06° 
0.27 ± 
0.14 
 
aTarget DNA amplicons derived from homozygous wt/wt samples. b Interferent: fragmented genomic DNA 
(80 ng) and/or unrelated PCR amplicons (300 pg each). 
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The shift signals did not differ between samples and DR values were all around the threshold value of 0.2 
as for the reference non-complex samples (row without interferent), supporting the correct identification of 
wild type samples for all of the three investigated alleles. 
Further analyses are on-going to verify the lower limit in sample cellularity in order to reliably detect the 
presence of mutated sequences in the CFTR gene responsible for CF disease without PCR-mediated 
amplification. 
 
3.3.5 System cut-off evaluation and test with blind samples 
After the evaluation of the DRs deriving from all the genotyping experiments performed and summarised 
in the previous paragraphs, DR cut-offs were established and are reported in Table 8. A DR cut-off for wt 
sample genotypisation can be set at 0.4: all the obtained DRs below 0.4 univocally genotype a wt sample; 
vice versa a DR above 0.5 genotypes univocally the presence of a mutant allele. In particular, the presence 
of a heterozygous sample is characterised by a DR value in the range between 0.5 and 3.0, as verified in 
the performed experiments. 
 
Table 8. Summary of genotypisation DRs cut-off range obtained using fluorescent technique (a) or SPR 
technique (b). 
 
 
(a) fluro analysis 
 
(b) SPR analysis 
DR output results DR output results 
wild type Hetero wild type hetero 
mut/wt probe signal <0.4 0.5–1.5 mut/wt probe signal <0.4 0.5–3.0 
 
To validate the genotypisation-established cut-offs, human DNA samples were PCR amplified and 
analysed through the SPR platform, in a blind experiment, running a fluorescent microarray experiment as 
a control. 
In particular 4 samples - ΔF508 wild type and heterozygous samples plus N1303K wild type and 
heterozygous samples - were analysed in duplicate on the plasmonic gratings. Results are reported in 
Figure 30, in which shifts are represented as dots on a graph delimited by the DR cut-off lines. For all the 
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analysed sample’s replicas, a correct genotyping is achieved, as shown in the graph. The shifts of wild type 
samples are below the 0.4 line, while all heterozygous samples present signals above the 0.5 line. 
 
 
 
Figure 30. Genotypisation of CF samples for the positions related to ΔF508 or N1303K alleles in a blind 
experiment. The red line represents the DR cut-off for wild type samples, while the blue line points to the 
lower limit of the DR for heterozygous samples. Red dots and black squares represent replicas of the 
relative wild type samples, while green and blue triangles represent replicas of the relative heterozygous 
samples.  
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3.4 Conclusions 
In this Section experiments aimed at the set-up of a plasmonic-based platform for the identification of the 
most common CF causing mutation among the Italian population were described. 
Probes for CFTR screening were chosen, and their structure was evaluated. A precise and reproducible 
method for plasmonic gold surface functionalization was optimised for the genotyping of the three most 
frequent CFTR in the Italian population. Hybridisation conditions for correctly genotyping PCR fragments 
deriving from DNA extracted from clinical samples were properly set using a fluorescent microarray 
technique. Once optimised, hybridisation conditions were used for samples analysis on SPR substrates. 
Data obtained from plasmonic analysis demonstrated to be fully consistent and homogeneous between 
replicas, indicating the correct genotypisation of the selected alleles. These results clearly showed the 
possibility of employing azimuthally controlled GC-SPR for the genotypisation of CF mutations, and the 
discrimination between homozygous and heterozygous state could be improved further by finely 
controlling hybridization parameters to increase the number of the simultaneously detectable mutations. 
Moreover, the presence of interferent unrelated DNA did not affect the genotyping ability of the optimised 
SPR system. 
Further analyses will be performed to establish if the SPR technique could correctly identify mutations also 
in non-amplified samples, possibly even with the introduction of SPR enhancers. 
Results shown in the experiments of the present Section are the starting point for the realization and 
improvement of a GC-SPR based sensor that could be easily integrated in a diagnostic prototype thanks to 
the high sensitivity reached by the azimuthally rotated approach and to the system scalability. In fact, even 
if all the SPR measurements were performed by using a spectroscopic ellipsometer, requiring an expensive 
and quite complex readout, the detection system could be easily miniaturised developing a compact 
prototype as demonstrated in previous works18,23, leading to a low cost, label-free mutation screening, with 
the possibility of integrating the system in a lab-on-a-chip device with temperature and microfluidic 
control, and suitable also to be used by non-qualified personnel. 
In addition, using a CCD camera for the plasmonic signal collection, a parallel readout of multiple 
reactions onto the same substrate could be possible, making the sensing system comparable and 
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complementary to the fluorescence-based detection method. The ability of SPR technique to correctly 
identify unamplified samples is now under investigation to reduce the test running time. 
 
The results of this work produced the following publications: 
 
Peer Reviewed Journal: 
• Meneghello, A. et al. “Label-Free Efficient and Accurate Detection of Cystic Fibrosis Causing 
Mutations Using an Azimuthally Rotated GC-SPR Platform.” Analytical Chemistry. 86, 11773–
11781 (2014).25 
 
Abstract in International Conference Proceeding: 
• International Conference: “NanotechItaly 2013”, Venezia, Italy (2013): 
Meneghello, A. et al. “Surface Plasmon Resonance platform for the efficient and sensitive 
detection of Cystic Fibrosis causing mutations.” 
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4. Antibody platform for Legionella 
pneumophila bacteria detection 
In this Section, a work aiming at the exploitation of the SPR phenomenon to develop a fully automated 
platform for fast optical detection of Legionella pneumophila pathogens is described. 
The legal limit of L. pneumophila concentration in a high-risk hospital environment in Italy is 102 CFU/L 
(colony forming unit per litre), and the gold standard for its identification is a time consuming 
microbiological culture method. Starting from these considerations a sensitive azimuthally-controlled GC-
SPR system was applied to the detection of L. pneumophila to test the detection limit of the developed 
sensing device in term of specificity and sensitivity. The detection was accurately set up and precisely 
optimised firstly through the usage of flat gold functionalised slides to be then translated to sinusoidal gold 
gratings for label-free grating-coupled plasmonic (GC-SPR) detection using ellipsometer, in order to 
ensure reproducible and precise bacteria identification. 
Through azimuthally-controlled GC-SPR 10 Legionella pneumophila CFU were detected, while in the case 
of fluorescence analysis results, a negative readout is obtained if incubating less than 104 CFU. 
This detection platform could be further implemented as a prototype in which water and air samples will 
be sequentially concentrated, injected into a microfluidic system, and delivered to the SPR sensor for 
analysis. 
 
4.1 Introduction 
4.1.1 Pathogen biosensing: overview and focus on Legionella 
In the last decades there has been an increasing interest in sensitive, specific and fast biosensors to address 
several industrial and societal needs. In particular, reliable and fast detection of pathogenic bacteria in 
food, water, and air is a key challenge in biosensing due to the strong impact on health. Standard 
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microbiological methods based on cell culture and plating are highly efficient in the identification of 
bacterial strains, but they are very time consuming as identification and enumeration of the investigated 
bacteria require several days. In addition, most of these conventional methods require a biological facility, 
thus they are not suitable for on-site analysis and cannot be carried out by untrained personnel. Therefore, 
new biosensing devices, capable of detecting pathogens in a faster and equally accurate manner, are 
needed and, for this purpose, a multidisciplinary approach is essential to develop such platforms for 
contributing to solve significant societal challenges. 
Among pathogenic bacteria, Legionella pneumophila is of particular concern because its ability to colonise 
water systems, pools, air-conditioning systems (Figure 31) and thus spreading in close environments, it 
can endanger the health of individuals such as elderly and immunocompromised people (Figure 32).92 
Thus, a more accurate microbiological control is required, most notably in hospitals (operating rooms, 
laboratories, critical asepsis rooms, wards, common areas), but also in industrial and travel-associated 
environments as suggested by ECDC (European Centre for Disease Prevention and Control) data 
(http://ecdc.europa.eu/en/Pages/home.aspx). 
Favourable conditions for bacteria growth are also found in plants for the production of sanitary hot water 
and in evaporative cooling towers (30-50 °C with a relative humidity of 60-99%). 
 
 
 
Figure 31. Distribution of sampling sites testing positive for Legionella, EU/EEA, 2013. 
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Figure 32. A) Notification rates of Legionnaires’ disease per million, by sex and age group, EU/EEA, 
2013. B) Reported case-fatality of Legionnaires’ disease by sex and age group, EU/EEA, 2013. 
 
According to EU 2013 data (Figure 33) the three largest reporting countries (France, Italy and Spain) 
accounted for 58% of cases, and the six largest countries (France, Italy, Spain, Germany, the Netherlands 
and the United Kingdom) together reported 83% of cases. Italy accounted for the majority of the reported 
cases (1345 cases per million). 
 
 
 
Figure 33. Reported cases and notifications of Legionnaires’ disease per million, by reporting country, 
EU/EEA, 2013. 
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The perspective of this study consists in performing the whole SPR-based protocol for pathogen detection, 
from air/water sampling to L. pneumophila detection, in a fully automated prototype system and with 
specificity and sensitivity consistent with EU guidelines (The European Working Group for Legionella 
Infections (EWGLI) http://www.ewgli.org; ESCMID Study Group for Legionella Infections (ESGLI) 
https://www.escmid.org/research_projects/study_groups/legionella_infections). 
Even though several SPR-based sensors are already on the market for the detection of biomolecules, the 
development of an SPR sensor for detection of bacteria faces significant challenges, as: 
• High sensitivity and low detection limit of the biosensor are of key importance: because pathogenicity 
is very high, even the presence of small amounts of pathogens (<100 bacterium cells) can be a risk for 
health and therefore must be traced. 
• Selectivity towards target pathogen detection is critical to avoid both false-positive and false-negative 
results: in order to have a reliable readout, the sensitive surface must be selective for L. pneumophila 
bacterium cells, show non-selective adsorption of species and include positive and negative internal 
control. 
• Short analysis times (i.e. requiring hours instead of days of present microbiological techniques) are 
essential to trigger a quick response and put into action the necessary measures, such as water/air 
disinfection and physical examinations on the exposed humans. 
• Ease of use, possibility of on-site monitoring and automation of the sample manipulation and 
detection procedure are significant factors for frequent environmental monitoring and use by 
untrained personnel. 
• The whole delivery of samples from the sampling unit to the sensing unit must ensure efficient 
delivery of the bacteria. 
• The size of the device should allow samples to be analysed at the point of need rather than in a 
separate laboratory, allowing reduction of cost per single measurement and increase in throughput. 
Biochemical and molecular sensing of pathogens can be roughly divided into immune sensing and 
amplified nucleic acid detection. Whereas the latter approach detects specific DNA or RNA sequences of 
target cells/bacteria, and typically requires an amplification/labelling step of the target nucleic acids prior 
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to measurement, immunosensing is based on the strong interaction between antigens on the target cells and 
specific antibodies immobilised on the sensing surfaces, through which antibody-antigen conjugates are 
formed. These conjugates can be detected using different methods, including fluorescence, 
luminescence93,94, electrical or electrochemical impedance95, cantilever96,97, quartz crystalline microbalance 
(QCM)96, magneto-resistivity98 and SPR.93 
Among these sensing techniques, SPR sensors provide an extremely sensitive and versatile tool for 
miniaturised label-free sensing platforms integrated into lab-on-chip systems for potential applications in 
environmental monitoring, biotechnology, medical diagnostics, drug screening, food safety and security.7 
Currently, SPR is widely adopted for the detection of biomolecules or to study binding interactions 
between biomolecules such as nucleic acid-nucleic acid, nucleic acid-proteins, carbohydrate-protein, and 
lipid-protein.7 Detection and investigation of viruses, bacteria and eukaryotic cells is nowadays becoming a 
rapidly growing field in SPR biosensing (Figure 34). 
 
 
 
Figure 34. A schematic of a standard surface plasmon resonance (SPR) detection principle and readout. 
(a) A resonance angle can be identified for incident light shining on a thin metal surface such that the light 
is converted to surface plasmons and very little light is reflected back from the surface. (b) When 
recognition elements, such as antibodies, are attached, the refractive index at the surface changes and the 
resonance angle shifts, causing an increase in the reflectivity for a fixed incident light angle. (c) The 
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resonance angle shifts again when cells bind to the antibody. The shift is proportional to the size and 
surface density of the attaching objects. Figure adapted from99. 
 
Several studies have been published on SPR-based methodologies for detection of various bacterial species 
such as Escherichia coli O157:H7100–102, Staphylococcus aureus103, methicillin-resistant Staphylococcus 
aureus104 or Vibrio cholerae105 but the detection was only achieved in laboratory settings. This limitation 
should be overcome by a new device architecture providing simultaneous positive and negative control to 
yield reliable measurement readouts in presence and absence of Legionella bacterial cells. 
Different SPR sensing architectures and transduction systems have been explored to improve sensing 
performance. A novel grating-coupled SPR (GC-SPR) configuration under azimuth and polarization 
control will ensure sensitivity, as well as provide the requirements for new compact and integrated 
systems. A typical feature of SPR is its label-free approach: labelling of the analyte with a chemical or 
optical tag is not required, which is a clear advantage considering that the labelling procedure may modify 
and/or disrupt the target-probe interaction, and the lack of a labelling step simplifies automation. 
Due to the enhanced sensitivity of this configuration compared with conventional SPR, the possibility of 
detecting low amounts of biological species with high accuracy has already been demonstrated.97,98 This 
feature will be exploited for the detection of L. pneumophila within the concentration limits fixed by EU 
guidelines. 
Specificity will be provided by the immuno-functionalization of the plasmonic surface using anti-L. 
pneumophila antibodies. In order to take complete advantage from SPR sensitivity, the surface of the 
optically-active surface needs to be suitably coated with a biorecognition element able to bind the specific 
analyte, and to be passivated to prevent non-specific adsorption onto the plasmonic sensitive surface. The 
work was focused on a case study involving the L. pneumophila pathogen, but one future application could 
include the extension of the proposed GC-SPR-based approach to other pathogens’ monitoring, through 
possible modulation of SPR grating parameters and instrumental settings in a multiplexing format. 
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4.1.2 Legionella pneumophila and legionellosis 
Legionella pneumophila is a thin, aerobic, pleomorphic, flagellated, non-spore forming, Gram-negative 
bacterium of the genus Legionella. Bacteria dimensions range from size from 0.3 to 0.9 mm in width and 
from 1.5 to 5 mm in length (Figure 35), while in culture filamentous forms up to 20 mm can be frequently 
found. The cell wall of these organisms is characterised by the presence of branched-chain fatty acids that 
are not usually present in Gram-negative bacteria.106 
L. pneumophila, an intracellular parasite of free-living protozoa, is the causative agent of Legionellosis 
(Legionnaires' disease) that is a serious form of pneumonia, with a case-fatality ratio on the order of 10-
15%. Recognised risk factors for Legionnaires' disease - which could increase the fatality rate up to 80% - 
include belonging to an older age group (>50 years), male, having a chronic underlying disease with or 
without an associated immunodeficiency and being a heavy cigarette smoker.107 
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Figure 35. A) TEM image of Legionella pneumophila bacilli (picture from CDC/ Dr. Francis Chandler, 
ID#: 1187); B) TEM image of Legionella pneumophila multiplying inside a cultured human lung 
fibroblast. Multiple intracellular bacilli, including dividing bacilli, are visible in longitudinal and cross 
section (picture from CDC/ Dr. Edwin P. Ewing, Jr., ID#: 934). 
 
Although 42 different species of Legionella have been described, not all associated with human disease108, 
L. pneumophila is the species most often detected in diagnosed cases. The European Working group for 
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Legionella Infections (EWGLI) and the European Legionnaires’ Disease Surveillance Network (ELDSNet) 
have reported 4897 cases of Legionellosis in 2011 in EU Member States, Iceland and Norway.109,110 
L. pneumophila is found in aquatic habitats, especially in potable water, air conditioning, hot and cold 
water systems, cooling towers, evaporative condensers, spa/natural pools, healthcare facilities and, more in 
general, in high accommodation capacity structures.111 Legionnaires’ disease is normally acquired through 
the respiratory system by breathing in air that contains L. pneumophila in an aerosol, especially made of 
droplets with a diameter of less than 5 um, that can reach the lower airways more easily. 
The standard technique for detection and monitoring of this pathogen is microbiological bacterial culture, 
which is based on the in vitro selective growth of bacteria (ISO 11731: 1998 and ISO 11731-2: 2008). 
Whereas this approach is very accurate and allows for extremely low detection limits (a single CFU can be 
detected), it has essentially three disadvantages: (1) it requires dedicated microbiology laboratories, (2) it 
must be performed by highly specialised personnel, and (3) delivery of test results may take up to several 
days (more than 7 days are usually required). 
Whereas the sensitivity and detection limit of bacterial culture tests can be hardly achieved by other 
instrumental techniques, such detection approach is not suitable for high-frequency L. pneumophila 
environmental monitoring (i.e. delivery of results on the order of hours and tests repeated on a daily basis). 
Since Legionella is a widespread pathogen and has a relatively high case-fatality ratio, it should be clear 
that outbreaks should be caught at their early onset in order to trigger a quick response, putting into action 
the necessary countermeasures as soon as possible, such as water/air disinfection and physical 
examinations on the exposed humans. This is even more evident considering that crowded environments 
and large infrastructures might exacerbate the consequences of an outbreak, in particular when hospitalised 
debilitated patients are involved or other risk groups such as children and the elderly. Standard culture 
methods, therefore, appear unsuited for the environmental monitoring against Legionella threats. 
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4.1.3 Aim of the study 
Based on the considerations illustrated above concerning Legionella, the existence of a gap between the 
actual health risk and the possibility to manage this risk, e.g. enforcing suitable disinfection and treatment 
countermeasures, is a major concern: the need to close this technological gap responds to the societal 
challenge of having safer and more healthy environments. 
The study was focused on the development of a sensitive azimuthally-controlled grating coupled-SPR 
system for the identification of L. pneumophila. Experimental protocols were first set up with fluorescent 
microarray technique firstly through the usage of flat gold functionalised slides. Results were translated to 
sinusoidal gold gratings for label-free GC-SPR detection using ellipsometer, in order to ensure a 
reproducible and precise bacteria identification and take advantage of the high sensitivity of the GC-SPR 
configuration to increase the performances of our sensing device in terms of detection limit (detectable 
bacterium CFUs) and output time. 
Experimental validation of the functionalised sensing surface demonstrated the high specificity of the 
platform in detecting L. pneumophila with low cross-reaction signals due to the presence of other 
Legionella species and no signal when bacteria other than Legionella were present in the sample. Moreover 
the sensing GC-SPR unit was able to recognize the presence of as few as 10 CFUs of L. pneumophila in 
the incubated sample. These results indicate the possibility to scale the sensing unit in an automated and 
controlled device for Legionella pneumophila detection. 
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4.2 Materials and Methods 
4.2.1 Marketing antibodies evaluation and deposition 
Anti Legionella pneumophila antibody were selected among commercially available molecules, from most 
competitive suppliers in terms of quality/cost ratio. 
Required characteristics to satisfy experimental needs were: 
o polyclonal: for the recognition of multiple epitopes to ensure efficient capturing and detection 
o unconjugated: acting as capture antibody for the label-free detection (cost reduction) 
o obtained immunising with whole cells/live cells: to allow the recognition of native antigens and 
intact whole cells that will be present in the environment 
Two anti Legionella pneumophila antibodies with the desired features were chosen (Table 9): 
o rabbit polyclonal antibody 
o unconjugated 
o obtained immunising with a whole cell preparation of L. pneumophila (ATCC #33152) 
o not absorbed 
o one of the 2 indicating as reactive towards L. pneumophila serogroups 1-12 in IFA. Recognizes all 
antigens of intact microorganism 
Gold slides were cleaned, PEGylated, functionalised and blocked as described in Section 2, as well as e-
surf microarray slides, used as parallel fluorescence microarray control. 
Concerning gold slides, two types of substrates were used: 
o gold flat slides: they present a planar surface, the antibody was deposited through the microarray 
spotter and they were analysed through microarray laser scanner. 
o gold sinusoidal slides: the antibody was deposited through the usage of the ProPlate multi-well 
mask in order to have multiple wells to be incubated and analysed through label-free SPR. 
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Table 9. Specifications of the two anti L. pneumophila selected antibodies. 
 
 
Virostat Legionella pneumophila IgG 
polyclonal antibody (#6051) 
Abnova Legionella pneumophila polyclonal 
antibody (#PAB13999) 
Host animal Rabbit Rabbit 
Immunogen 
A whole cell preparation of Legionella 
pneumophila; ATCC #33152 
Native from Legionella pneumophila 
Specificity All antigens of intact microorganism 
Reacts with L. pneumophila serogroups 1-12 in 
IFA. Recognizes all antigens of intact 
microorganism. Antiserum is not absorbed and 
may cross-react with related microorganisms 
Cross reactivity 
Antiserum is not absorbed and may cross-react 
with related microorganisms 
Antiserum is not absorbed and may cross-react 
with related microorganisms 
Storage buffer 
phosphate saline buffer (0.01M, pH 7.2) 
containing 0.1% sodium azide 
10 mM PBS, pH 7.2 (0.09% sodium azide) 
Concentration 1 ml, 4-5 mg/ml 100 μl, 4-5 mg/ml 
 
The following antibodies were used: 
 Virostat (Portland, ME, USA) IgG α Legionella pneumophila polyclonal antibody (#6051) 
 Abnova (Taipei, Taiwan) IgG α-Legionella pneumophila rabbit polyclonal antibody (#PAB13999) 
 Invitrogen IgG1 anti-biotin mouse monoclonal antibody (clone Z021), 1 mg/ml, as negative control 
 Invitrogen Goat anti-mouse IgG Secondary Antibody, Alexa Fluor® 532 conjugate (#A-11002) or 
Alexa Fluor® 647 conjugate (#A-21235), as fluorescence controls. 
Up to 48 identical sub-arrays were spotted per slides. 
 
4.2.2 Protocols for bacteria culture, processing and identification  
4.2.2.1 Bacteria strains and culture 
The following bacteria strains were used: 
 Legionella pneumophila subsp. pneumophila (ATCC 33152) serogroup 1 (BSL2) 
 Fluoribacter dumoffii (ATCC 33343) (BSL2) 
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 E. coli DH10-β (New England Biolabs, Ipswich, MA USA): as negative control (BSL1) 
Legionella - defined as fastidious bacterium i.e. a bacterium that has a complex nutritional requirement - 
do not grow on standard culture media112, but needs L-cysteine and iron to grow. Culture media and 
supplement for Legionella, purchased from Biolife Italia (Milano, Italy), whose formula is reported in 
Table 10, were the following: 
 Legionella BCYE (Buffered Charcoal Yeast Extract) Agar Base 
 Legionella BCYE α-Growth Supplement 
 
Table 10. Legionella BCYE Agar Base formula (left) and Legionella BCYE α growth supplement (right). 
 
 
Legionella BCYE Agar Base 
Typical Formula mg/litre 
Activated charcoal 2.0 
Yeast extract 10.0 
Agar 13.0 
 
 
Legionella BCYE α  growth supplement (vial contents for 500 ml of medium) 
Typical Formula mg/litre 
ACES Buffer/Potassium hydroxide 6.4 g 
α –ketoglutarate 0,5 g 
Ferric pyrophosphate 125.0 mg 
L-Cysteine HCl 200.0 mg 
 
  
 
Legionella selective agar was prepared following the supplier protocol: 
Suspend 12.5 g in 450ml of cold distilled water. Heat to boiling with agitation and sterilise by autoclaving 
at 121°C for 15 minutes. Cool to 50°C and add the contents of one vial Legionella BCYE α Growth 
Supplement reconstituted with 50 ml of sterile, warm distilled water (50°C). Mix well and distribute into 
sterile Petri dishes. Final pH 6.9 ± 0.1. 
The colony morphology of Legionella pneumophila on the plating media after 48-72 hours of incubation is 
as follows: diameter 1-2 mm (increase in size on further incubation), white, glistening, circular, smooth, 
raised with entire edge. 
E. coli was cultured in TSA (Table 11), prepared following the supplier protocol (Biolife Italia): 
Suspend 40 g in 1000 ml of cold distilled water. Heat to boiling with agitation and sterilise by autoclaving 
at 121 °C for 15 minutes. Cool to 50 °C, mix well and distribute into sterile Petri dishes. Final pH 7.3 ± 
0.2. 
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Table 11. TSA formula. 
 
TSA 
Typical Formula mg/litre 
Tryptone (Pancreatic Digest of Casein) 15.0 
Soytone (Papaic Digest of Soybean Meal) 5.0 
Sodium Chloride 5.0 
Agar 15.0 
 
4.2.2.2 Colony forming unit (CFU) number evaluation 
For correctly testing the system sensitivity, the measurement of the content of colony forming units per ml 
of a solution was made dissolving specific colonies in physiological solution (NaCl 0.9 % w/v) and 
correlating the solution optical density (OD600) to the number of colonies on agar plates seeded with 
dilutions starting from known OD, after 72 hours of incubation. Counting the number of colonies 
corresponding to each dilution, the content in CFU for a specific OD was therefore defined, and data are 
summarised in Table 12. 
 
Table 12. OD600-CFU correlation for the investigated bacteria. 
 
Specie CFU/ml at OD600 = 0.15 
Legionella pneumophila 1.5*108 
Legionella dumoffii 1.2*108 
Escherichia coli 0,2*109 
 
4.2.2.3 Labelling and binding protocol for bacteria cells 
Protocols and procedures were tested and optimised to properly manipulate and label bacteria cells. 
Selected colonies were picked and dissolved in physiological solution. To remove any agar residual, 
colonies were washed 2 times in 1X PBS + 0.5% FBS (Fetal Bovine Serum), pH 7 and kept at 4 °C for few 
days or frozen in a solution of 1XPBS, 10% FBS and 15% glycerol. 
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Fluorescent labelling of bacteria was performed as follow: colonies were recovered, washed and 
resuspended in 1X TBS/FBS buffer (50 mM Tris-HCl, 150 mM NaCl, 0.05% FBS, pH 7.5). OD600 was 
spectrophotometrically determined and solution was diluted to the appropriate OD600 corresponding to the 
desired CFU amount. Bacteria labelling was performed with NHS ester (succinimidyl ester) of Alexa 
Fluor® 555 or 647 (Invitrogen): these esters are popular tool for conjugating Alexa dye to a protein or 
antibody through their primary amines, obtaining a conjugate with bright fluorescence and great 
photostability. Known amount of bacteria cells (typically 108 CFU) were labelled with 30 μg of NHS ester 
Alexa (resuspended in 5 μl of DMSO) for 1h at room temperature and under gentle shaking. 
Cells were then washed 3 times in 1X TBS/FBS 1X to remove the excess of unbound fluorophore and then 
resuspended in 1X TBS/1% BSA, buffer selected for bacteria incubation on the slides, that was performed 
for 1 h at RT in gentle shaking. After incubation, solutions were removed and wells were washed once 
with Protein washing buffer (50 mM Tris, 250 mM NaCl, 0.05% Tween 20, pH 7.0) and twice in 1X PBS. 
Slides were finally spin dried and analysed for fluorescence response through laser scanner. Unlabelled 
cells were manipulated and diluted in the same way except for the labelling step, and slides were analysed 
for SPR response through ellipsometer. 
 
4.2.2.4 Antibody labelling for “sandwich” fluorescent detection  
Concerning fluorescent detection, bacteria cells were recognised directly - through fluorescent cell 
labelling - or indirectly - through fluorescent antibody labelling. Antibody labelling was performed as 
follow: 2 μg of antibody per well were labelled with NHS ester of Alexa Fluor® in a 1:4 molar ratio. 
Labelling was performed for 1 hour at RT and the mix was diluted in 1X TBS/1% BSA to stop the 
reaction, that was incubated on the slides as described previously. 
 
4.2.2.5 Bacteria cell fragmentation 
Bacteria cell fragmentation was achieved resuspending cells in physiological saline solution and 
performing three freezing cycles (-80 °C for 30 minutes and 37 °C for 5 minutes with subsequent vortexing 
for 2 minutes). Viable CFU evaluation after such treatment was performed by plating treated samples: the 
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fragmentation treatment efficiency was higher than 99.99%. Fragmented cells were used to validate the 
antibody ability to recognize and bind fragmented versus whole cells. 
4.2.3 Microfluidic cell for SPR measurements 
For Legionella incubation on functionalised gratings and subsequent reflectivity measurements, a 
microfluidic cell (Figure 36) (JA Woollam and Co., Inc. - CA, USA) was used to perform the acquisition 
of SPR spectra. 
 
 
 
 
 
Figure 36. Microfuidic cell used for SPR experiment (LiquidCell Manual TLC-300, J.A. Wollam and Co., 
Inc). 
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Due to the closed structure of the cell and the presence of a single inlet and outlet port, the incident light 
beam enters the microfluidic cell according to a fixed angle, determining the possibility of analysing one 
sample at a time. Therefore, in every experimental session one single grating was employed, anchored to 
the base of the cell in a stable way for the whole experimental procedure and analysis. 
SPR measurements were performed as described in Section 2, in particular substrates were characterised 
after each experimental step with the parameters of Table 13. 
 
Table 13. Characterisation parameters used for SPR measurements. 
 
Incident wavelength [nm] 600-800 
Light incidence angle [°] 70 
Azimuth [°] 45° 
Polarization [°] 140° 
 
Reflectivity measurements were carried out in the following steps: 
o after piranha cleaning, substrate anchoring to the cell base and definition of a grating experimental 
area; 
o after PEG o/n functionalisation, washing and drying, antibody deposition o/n inside the experimental 
area and blocking; 
o after L. pneumophila incubation on the functionalized area, washing, frozen ethanol fixation and 
drying. 
The described procedure allowed to control all the experimental steps with high precision and accuracy in 
order to be able to reproduce the optimised experimental condition. A well-defined functionalisation area 
was delimited by the o-ring (Figure 37). 
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Figure 37. Picture of an SPR where the o-ring delimited region (8x21mm) and the incidence light spot are 
visible. The functionalisation area was defined by drawing an ellipse-like shape with an alcohol resistant 
pencil. 
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4.3 Results and Discussion 
4.3.1 POSEIDON Project (ICT-26 Horizion 2020) 
During my PhD work I’ve been involved in Surface Plasmon Resonance project for the detection of 
Legionella pneumophila: obtained results were used as preliminary data for the preparation and submission 
of a Horizon 2020 project, which has been approved and started on January 2015. 
The results illustrated in this Section (4.3 Results and Discussion) have been therefore obtained as 
preliminary data and internal results of POSEIDON project (Plasmonic-based autOmated lab-on-chip 
SEnsor for the rapid In-situ Detection of LegiONella), focused on the specific detection of Legionella 
pneumophila (ICT-26-2014-I RIA, G.A. 644669). 
The project aims at the exploitation of the SPR phenomenon to develop a fully automated platform for fast 
optical detection of L. pneumophila. This detection platform will be implemented as a prototype in which 
water and air samples are sequentially concentrated, injected into a microfluidic system, and delivered to 
the SPR sensor for analysis. The designed system will allow for its future integration in water distribution 
and HVAC (heating, ventilation and air conditioning) for prevention of L. pneumophila outbreaks. A 
schematic overview of the project approach is summarised in Figure 38. 
The partnership is composed by: Italy (Veneto Nanotech s.c.p.a., Clivet s.p.a., ARC - Centro Ricerche 
Applicate s.r.l.), Spain (CatLab), Sweden (Uppsala University) and Netherlands (Metrohm Applikon). 
From December 2015 Veneto Nanotech is no more involved in the project because of company financial 
issues, and working packages involving Veneto Nanotech expertise were moved to other partners, and a 
new Italian partner, Protolab s.r.l., has been involved in the project. 
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Figure 38. Schematic overview of POSEIDON project depicted visualising the different system 
components and the partners’ involvement in their development (see legend) and the connection in the 
workflow. 
 
4.3.2 Antibody binding evaluation 
A first set of experiments was performed to verify the antibodies ability to recognize Legionella 
pneumophila and dumoffii cells. Recorded fluorescence values were compared to define the discrimination 
ability of the two selected antibodies. In these first experiments, standard e-surf slides were used, since 
their characteristics of reliability and reproducibility were already know in the laboratory. 
Colonies of Legionella pneumophila or Legionella dumoffii were diluted in physiologic solution, 
quantified through OD600, labelled and incubated as described in Materials and Methods section. 
The two selected anti-Legionella antibodies (purchased by Virostat and Abnova) were able to recognize 
with completely overlapping efficiency Legionella pneumophila cells. A partial reactivity was observed 
also when incubating Legionella dumoffii cells, and the two antibodies shows also in this case similar 
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binding capability. Data are reported graphically in Figure 39 and are representative of at least three 
independent replicas. 
  
A B 
 
Figure 39. Binding efficiency recorded on microarray e-surf slides functionalised with anti-Legionella 
antibodies (Virostat - in blue versus Abnova - in red) when incubating the same amount of fluorescently 
labelled (Alexa Fluor 555) L. pneumophila (A) or L. dumoffii (B) cells. 
 
As can be observed by the recorded fluorescence intensity, selected polyclonal antibodies were able to 
recognize in a highly specific way L. pneumophila cells (A.U. 35000 ± 10%) if compared to L. dumoffii 
ones (1100 ± 10%), with a signal at least 1 order of magnitude higher when recognising L. pneumophila. 
Also if specific information about the cross-reactivity ability of the two antibodies is not fully 
characterised by the supplier, both antibodies are produced from rabbit immunised with L. pneumophila 
ATCC 33152, can react with all the 12 serogroups of L. pneumophia, and can partially cross-react with 
other Legionella species.
Fluorescence signals recorded incubating labelled Legionella on negative control antibody are not 
significant (A.U. <100), as expected, revealing absence of cells aspecific interaction (data not shown). 
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4.3.3 Bacteria capturing demonstration through confocal and scanning 
electron microscopy 
After demonstrating the antibody binding ability concerning Legionella detection, a further demonstration 
of bacteria capturing was achieved directly, through both confocal and scanning electron microscopy 
(SEM). 
A microarray slides properly functionalised with α-Legionella antibody and incubated with Alexa 555-
labelled L. pneumophila cells was used for the imaging experiment, reported in Figure 40. 
Both fluorescence confocal microscopy and scanning electron microscopy images were collected. Used 
scanning electron microscope is designed for high as well as low vacuum operating, giving the possibility 
of examination of non-conducting, water containing specimens in their natural state at low vacuum 
conditions in microscope chamber. 
As can be nicely seen, a peculiar green fluorescent pattern is revealed through confocal microscopy, due to 
bacteria capturing only on the region delimited by the microarray spots, and the same peculiar pattern is 
revealed after metallisation and scanning electron microscopy. No signal is detectable on the surrounding 
regions, demonstrating an optimal surface passivation and absence of aspecific interactions with the 
background surface. 
L. pneumophila cultured cells appear, as reported in literature113, mainly as filamentous clusters and in 
minor part as road-shaped bacteria. 
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Fluorescence Confocal Microscopy 
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Figure 40. Fluorescence confocal microscopy (upper panels) and Scanning electron microscopy (lower 
panels) of Legionella pneumophila cells incubated on α-Legionella functionalised microarray slides. 
 
4.3.4 Direct vs indirect bacteria detection 
Antibody selection performances were evaluated directly, using fluorescently labelled bacteria, or 
indirectly, performing a “sandwich” indirect detection. Legionella cells were incubated as Alexa Fluor 555 
labelled or unlabelled. For the “sandwich” detection the two α-Legionella polyclonal antibodies were 
labelled with Alexa Fluor 647 and used as detection probe. 
This experiment was performed to analyse if the “sandwich” detection could result in better performances 
when compared to the direct one, and if the bacteria labelling step could impair or worsen antibody 
recognition in a significant way. The experiment was performed to compare also in this setting the 
performances of the two selected α-Legionella polyclonal antibodies, used in alternative combination as 
capturing or as detecting molecules. 
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Obtained results are reported graphically Figure 41 A, B and C concerning L. pneumophila cells and in 
Figure 41 D, E and F concerning L. dumoffii cells. Detection of labelled cells trough a “sandwich” strategy 
is correctly obtained, and it is not significantly different if using Virostat or Abnova antibody, neither as 
capturing or detecting molecule. Only if detecting L. dumoffii using Abnova as detecting antibody and 
Virostat as capturing one (Figure 41 E) an improvement of the fluorescent readout is achieved, 
nevertheless comparable performances between the two antibodies are observed when performing a direct 
detection of L. dumoffii labelled cells (Figure 41 D). 
For the subsequent label-free SPR application a direct recognition performed can therefore be foreseen 
with one of the two antibodies as capturing layer, without specific preferences. 
Experiments were also performed with unlabelled cells recognised by labelled antibodies and demonstrate 
that fluorescent signals obtained with labelled cells plus labelled antibodies are not significantly different 
from the one obtained with unlabelled cells plus labelled antibodies (Figure 41 G and H): this result 
indicates that bacteria labelling – with the optimised fluorescent molecules ratio – did not impair antibody 
binding and did not lead to aspecific interactions. 
Eventual aspecific binding was also verified incubating labelled bacteria on unrelated antibody (α-biotin) 
with or without subsequent incubation with labelled α-Legionella antibody: in none of the cases a 
significant fluorescent signal was detected (Figure 42), demonstrating the absence of aspecific interaction 
events. 
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1. Fluorescent microarray readout incubating Alexa Fluor 555 labeled Legionella cells detected directly 
or through a “sandwich” Alexa Fluor 647 labeled antibody. 
 
A B C 
D E F 
2. Fluorescent microarray readout incubating unlabeled Legionella cells detected through a 
“sandwich” Alexa Fluor 647 labeled antibody. 
 
 
G 
 
H 
 
Figure 41. Graphical representation of direct vs indirect Legionella cells detection experiments. Blue 
histograms: Virostat antibody; red histograms: Abnova antibody. 1. A, B, C: L. pneumophila cells 
detection; 1. D, E, F: L. dumoffi cells detection. A and D: green fluorescent signal deriving from Alexa 
Fluor 555 bacteria labelling (direct detection) captured by Virostat antibody (blue) or Abnonva (red). Red 
fluorescent signal deriving from Alexa Fluor 647 Antibody labelling (indirect detection) detecting labelled 
bacteria captured with Virostat antibody (B and E) or with Abnova antibody (C and F) or detecting 
unlabelled bacteria captured with Virostat antibody (G) or with Abonova antibody (H). 
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Figure 42. Fluorescent microarray results obtained for direct vs indirect Legionella cells detection. 
Bacteria cells were used as Alexa Fluor 555 labelled or unlabelled. Detecting antibodies were used as 
Alexa Fluor 647 labelled.  
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4.3.5 Sensitivity evaluation of the fluorescent set-up 
Once confirmed and evaluated the ability to specifically recognize Legionella cells of the two selected α-
Legionella antibodies, experiments were performed to establish the fluorescent system sensitivity in terms 
of minimum detectable amount of bacteria CFU. 
Experiments were performed both on e-surf microarray glass slides and on flat gold slides, in order to 
evaluate and compare fluorescent signals, availability and performances of antibody anchored on gold 
through a SH-PEG-COOH linker: results obtained in terms of spots shape and quality appear to be 
improved when using gold slides, probably due to the compact antifouling PEG layer created on the slides, 
if compared to the polymeric layer available on commercial e-surf slides surfaces (data not shown). For 
this reason, results obtained on gold slides only are reported in this paragraph.
L. pneumophila and L. dumoffii bacteria colonies were collected, quantified, labelled with Alexa Fluor 555 
and appropriately diluted through serial dilution from known OD600, starting from 2x108 CFU/ml down to 
2x104 CFU/ml. Cells where finally incubated on the platform and results are reported both graphically 
(Figure 43) and as microarray fluorescent images (Figure 44): data are representative of at least three 
independent experiments. 
 
  
A B 
Figure 43. Graphical representation of sensitivity performances of α-Legionella antibodies incubated with 
serial dilutions of Alexa Fluor 555 labelled L. pneumophila (A) and L. dumoffii cells (B). 
 
Concerning fluorescent readout sensitivity for L. pneumophila up to 2x104 CFU/ml can be detected while 
for L. dumoffii fluorescent readout is not significant below 2x107 CFU/ml. As previously illustrated, the 
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two selected α-Legionella antibodies can react only partially and with low efficiency with L. dumoffii cells 
if compared to L. pneumophila cells, being them raised specifically for L. pneumophila specie, as indicated 
by the specifications and confirmed by fluorescence experiments. 
 
POST labelled Legionella incubation on Au flat surface 
Legionella pneumophila Legionella dumoffii 
Virostat capture Abnova capture Virostat capture Abnova capture 
2*108 CFU/ml 
    
2*107 CFU/ml 
    
2*106 CFU/ml 
    
2*105 CFU/ml 
    
2*104 CFU/ml 
   
0 CFU/ml 0 CFU/ml 
  
 
Figure 44. Microarray fluorescence images of sensitivity performances of α-Legionella antibodies 
incubated with serial dilutions of Alexa Fluor 555 labelled L. pneumophila and L. dumoffii cells. 
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4.3.6 Evaluation of ethanol fixation effect on sensitivity 
To test the bond stability and the possibility to block and stabilise bacteria on the slide, after bacteria cells
incubation gold slides were analysed for fluorescence, and then fixed in absolute ethanol (100%) for 15 
minutes at -20 °C. The experiment was performed on L. pneumophila incubated array. Slides were finally 
dried and fluorescence signals were acquired and compared with the signals recorded prior to fixation. 
As can be seen from Figure 45, the fluorescence signals recorded after ethanol fixation are not 
significantly different from the ones recorded prior to fixation (differences below 10%); in addition, there 
were no significant differences related to the usage of Virostat or Abnova antibodies: data represented in 
the graph are related to the usage of Virostat antibody as capture probe. 
Ethanol fixation has therefore been used for all the subsequent experiments prior to SPR measurements, to 
ensure a proper cell fixation. 
 
 
 
Figure 45. Graphical representation of sensitivity performances of α-Legionella antibodies (Virostat) 
incubated with serial dilutions of Alexa Fluor 555 labelled L. pneumophila pre (red) versus post (blue) 
ethanol fixation. 
 
4.3.7 Evaluation of system performances with whole vs fragmented cells 
An evaluation of the platform possibility to recognize also fragments of bacterial microorganisms was 
performed by cell fragmentation with an optimised freezing and thawing protocol described in Materials 
and Methods Section. 
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The analysis of cell viability after fragmentation has demonstrated a fragmentation efficiency > 99.99%: in 
Figure 46 vital Legionella colonies appear rich in long flagella around the cells (A and C) while after 
fragmentation cells are found only as fragmented portions or debris (B and D). The experiment was 
performed for both Legionella species. 
 
  
A B 
 
C D 
 
Figure 46. Whole Legionella cells (A: L. pneumophila, C: L. dumoffii) versus fragmented cells (B: L. 
pneumophila, D: L. dumoffii.10X magnification. 
 
After fragmentation cells were fluorescently labelled and incubated on microarray - at the concentration of 
2*108 CFU/ml and 2*107 CFU/ml - in parallel with unfragmented cells at the same concentration: recorded 
fluorescent intensities from fragmented cells are lower to the one recorded from whole cells for both 
species, of at least 50%. Furthermore, whole cells appear on the spots as compact fluorescent discrete 
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structures while fragmented ones appear as a fluorescent homogeneous spot, without particular 
distinguishable tridimensional structure (data not shown). 
Results indicate the ability of the platform to detect also the presence of fragments labelled cells, also if 
with lower efficiency. 
 
4.3.8 Florescence system performances with antibody deposition in 
microwells 
To simulate the pattern of antibody deposition that will be used for SPR setting, i.e. antibody deposited not 
as spots but incubating the deposition solution in the whole microwell, α-Legionella antibody was 
appropriate diluted and deposited on the slide delimited by cells of 12.25 mm2 (square of 3.5 mm * 3.5 
mm) through ProPlate 64 slide chamber multiwells. Slides were incubated overnight in a humidity 
chamber at 75% saturation, and then stored as previously described. 
Bacterial cells were labelled and properly diluted with concentrations ranging from 2*108 CFU/ml to 2*104 
CFU/ml. With wells functionalization it is not possible to perform a precise fluorescence quantification 
since the software is devoted to microarray spots analysis, but only a qualitative analysis comparing 
background wells and negative control wells (were no significant fluorescent signal is recorded) is 
possible. In this experimental setting it was possible to record a distinguishable fluorescence signal up to 
2*105 CFU/ml for L. pneumophila samples and up to 2x108 CFU/ml for L. dumoffii (Figure 47). 
Since for this experimental setting only a qualitative analysis was possible, this experiment demonstrate 
the correct antibody functionalisation and bio-recognition also when depositing the antibodies on the 
whole microwell: this functionalization will therefore be used for the subsequent SPR gold grating 
functionalization, in parallel with spots functionalisation on flat gold slides as fluorescence control, for 
each experimental SPR session. 
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2*104 CFU/ml 2*105 CFU/ml 2*106 CFU/ml 2*107 CFU/ml 2*108 CFU/ml 
L. pneumophila Alexa Fluor 555 labelled cells 
 
 Blank 2*107 CFU/ml 2*108 CFU/ml 
L. dumoffii Alexa Fluor 555 labelled cells 
 
 
Figure 47. Fluorescence images recorded on wells functionalised with α-Legionella antibody deposition 
in the microwells and incubated with different concentration of L. pneumophila and L. dumoffii Alexa 
Fluor 555 labelled cells. 
 
4.3.9 Grating functionalisation and SPR measurements setup with microfluidic 
cell 
The functionalisation of gold gratings used for bacteria detection experiments was optimized through a 
series of procedures to verify and define the manipulation techniques of a substrate anchored to the base of 
the cell adopted for these experiments. In this way it was also possible to define the procedure 
“checkpoints” that need to be recorded and verified through SPR measurement. Results allowed to define: 
1) functionalisation volumes, 2) functionalisation procedures, 3) washing procedures and 4) analysis area 
delimitation. All the procedures must ensure adequate precision, repeatability and safety of sample 
manipulation and analysis. 
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The following steps were performed and SPR measurements were recorded along the protocol, after each 
specific step, to collect statistical data and to evaluate the substrate behaviour: 
o SPR measurement (1) after piranha cleaning - bare grating 
o over night PEGylation 
o washing, drying and SPR measurement (2) 
o -COOH groups activation and overnight antibody binding 
o washing, drying and SPR measurements (3 not blocked) 
o surface BSA blocking, washing, drying and SPR measurement (3 blocked) 
o working area delimitation with alcohol-resistant pencil and SPR measurement (4) 
o surface ethanol fixation (4 EtOH) 
Each step was clearly detectable and statistical analysis was performed to obtain predictable and 
reproducible shift range representative of each step. Finally, an incubation protocol of Legionella cells on 
plasmonic gratings was defined as follow:  
a) grating cleaning and anchoring to the cell base; definition of a grating experimental area (with 
alcohol-resistant pencil); 1° SPR measurement (bare): recorded shift included between 0 and 0.1 
nm. 
b) surface o/n PEGylation, washing and drying; antibody deposition inside the delimited area (o/n 
RT) and blocking; 2° SPR measurement (PEG+Ab+blocking): recorded shift included between 6 
and 7 nm. 
c)  L. pneumophila incubation on the functionalized area; washing, frozen ethanol fixation and 
drying; 3° SPR measurement (PEG+Ab+blocking+bacterium): recorded shift proportional to the 
amount of incubated bacteria. 
 
4.3.10 Legionella pneumophila SPR detection - sensitivity and specificity 
Bacterium concentrations of 106, 104, 102, 10 CFU of unlabelled or Alexa Fluor-647 labelled cells – from 
the same cell batch - were tested for SPR and fluorescent analyses run in parallel, respectively. Negative 
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control samples were set using 104 CFU of E. coli as controls for anti-Legionella antibody capturing 
specificity. 
Results are reported graphically - for SPR - or as fluorescent images – for microarray - in Figure 48 and 
numerically in Table 14. 
As can be observed in all the replicas, through azimuthally-controlled GC-SPR it was possible to detect a 
concentration of 10 CFU, while in the case of fluorescence analysis results, a negative readout is obtained 
if incubating less than 104 CFU. The SPR shift corresponding to 10 CFU (i.e. 2.46±0.04) could allow to 
further improving the SPR detection sensitivity since negative controls recorded shift (i.e. 0.07±0.03, 
obtained using bacteria not belonging to the Legionella genus) was comparable to the measurement 
instrumental error (hundredth of nm). 
Possible variations between experimental sessions concerning the size of the functionalization areas – 
manually drew – could cause experimental variability related to the different dispersion surface of the 
incubating solutions. The different dispersion of the sample and therefore its local concentration may in 
fact be responsible for the lack of proportionality of the SPR shifts related to 104 and 102 CFU. 
Although SPR detection experiments concerning 104 and 102 CFU need to be further analysed since 
recorded data are not proportional for these dilutions, the results are reliable shift values are significantly 
higher than the ones recorded on negative controls, demonstrating the platform specificity. Post 
functionalisation shifts for all analysed grating are coherent and included in the range of 6.5-9.5 nm. 
Further tests will be performed for Legionella detection in microfluidic-integrated system, allowing 
validation and parallel analysis of samples/replicas and quality control for each experimental session. 
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SPR spectra - L. pneumophila Fluorescent microarray – L. pneumophila 
 106 CFU 105 CFU 104 CFU 103 CFU Blank
106 CFU 
 
 
     
104 CFU 
 
 
     
102 CFU 
 
 
     
10 CFU 
 
 
     
  
 
101 
104 CFU on negative control antibody 
 
 
     
 
Figure 48. SPR shift measurements performed on gratings for Legionella pneumophila detection. Each 
SPR experiment was run in parallel with a fluorescence microarray control experiment with the same 
cells’ batch. Different serial dilution and negative control are reported. Black dotted line: bare grating, 
blue line: functionalised grating (PEG+Antibody+Blocking), red line: test grating (bacterium incubation). 
 
Table 14. SPR platform results obtained incubating known amount of L. pneumophila. E. coli was used as 
negative control. 
 
Target Antibody 
Resonance wavelength shift after 
PEG, antibody and blocking [nm] 
Resonance wavelength shift after 
bacteria incubation [nm] 
L. pneumophila 106 C.F.U. α Legionella 9,68±0,04 46,30±0,12 
L. pneumophila 104 C.F.U. α Legionella 6,15±0,12 12,64±0,11 
L. pneumophila 102 C.F.U. α Legionella 7,04±0,05 13,60±0,05 
L. pneumophila 10 C.F.U. α Legionella 6,65±0,05 2,46±0,04 
L. pneumophila 104 C.F.U. no antibody 4,67±0,16 0,06±0,16 
E. coli 104 C.F.U. α Legionella 6.76±0.04 0.07±0.03 
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4.4 Conclusions 
In this Section, a sensitive GC-SPR system was optimised and applied to the detection of L. pneumophila 
to test the detection limit of the developed sensing device in term of detectable bacterium CFU. Through 
azimuthally-controlled GC-SPR, 10 CFU were detected, while in the case of fluorescence analysis results, 
a negative readout is obtained if incubating less than 104 CFU: bacteria concentration detected using GC-
SPR system was lower than the concentration detected through fluorescence microarray control method, 
allowing the overcoming of experimental limits. Negative control experiments, run in parallel with the E. 
coli, allowed also to verify the specificity of the detection method. 
This detection platform is going to be implemented as a prototype in which water and air samples will be 
sequentially concentrated, injected into a microfluidic system, and delivered to the SPR sensor for analysis, 
trough the European Horizon 2020 project “Poseidon”. 
 
The results of this work produced the following publications: 
 
Peer Reviewed Journal: 
• Meneghello, A. et al. Paper under preparation. 
 
Abstract in International Conference Proceeding: 
• International Conference: Advances in Biodetection & Biosensors, co located event with Advances 
in Microarray Technology, Single Cell Analysis Europe and Lab-on-a-Chip. Berlin, Germany 
(2014). 
Meneghello, A. et al. “Detection of nosocomial infections related pathogens through a novel 
plasmonic biosensor device.” Awarded as: Best poster in “Advances in Biodetection & 
Biosensors” conference. 
 
• International Conference: EuroNanoForum, Riga, Latvia (2015): 
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Pierobon, R. et al. “POSEIDON: Plasmonic-based automated lab-on-chip Sensor for the rapid In 
situ Detection of LegiONella.” 
 
• International Conference: Nanotech Italy 2015, Bologna, Italy (2015): 
Rinaldi, M. et al. “POSEIDON: Plasmonic-based Automated Lab-on-chip Sensor for the Rapid in 
Situ Detection of LegiONella”. 
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5. Conclusions 
My PhD Thesis work was aimed at the exploitation of the Surface Plasmon Resonance (SPR) phenomenon 
for the set-up of biosensing platforms for clinical and environmental applications. 
In particular, two types of SPR-based platforms were set-up and optimised: the first one was an 
oligonucleotide-based platform for the detection of Cystic Fibrosis (CF) causing mutations while the 
second one was an antibody-based platform for the detection of Legionella pneumophila whole cells. 
Sensing detection of cystic fibrosis DNA showed the possibility of employing azimuthally-controlled GC-
SPR for the genotypisation of human DNA PCR amplified sample from wild type and heterozygous 
samples. 
Data obtained from plasmonic analysis demonstrated to be fully consistent and homogeneous between 
replicas, indicating the correct genotypisation of the selected alleles. These results clearly showed the 
possibility of employing azimuthally controlled GC-SPR for the genotypisation of CF mutations. 
Furthermore, SPR genotyping was not impaired in samples containing unrelated DNA, allowing the 
platform to be used for the parallel discrimination of several alleles also scalable for a high throughput 
screening setting. Results shown in the experiments of the present Section are the starting point for the 
realization and improvement of a GC-SPR based sensor that could be easily integrated in a diagnostic 
prototype thanks to the high sensitivity reached by the azimuthally rotated approach and to the system 
scalability. 
Concerning antibody platform for Legionella pneumophila bacteria detection, a strategy for the 
exploitation of the SPR phenomenon to develop a fully automated platform for fast optical detection of 
Legionella pneumophila pathogens was investigated. Through azimuthally-controlled GC-SPR, 10 CFU 
were detected, while in the case of fluorescence analysis results, a negative readout is obtained if 
incubating less than 104 CFU. Successful results were obtained when incubating environmental derived 
samples. This detection platform could be further implemented as a prototype in which water and air 
samples will be sequentially concentrated, injected into a microfluidic system, and delivered to the SPR 
sensor for analysis. 
  
 
106 
 
Concluding, the peculiar Grating Coupled−Surface Plasmon Resonance sensing method applied for this 
Thesis work has revealed to be an accurate and highly sensitive strategy – with multiplexing possibility - 
for the sensing and detecting of different kind of biomolecules, from DNA fragments to whole bacteria 
cell, and in different kind of applications, from genetic disorders’ diagnostics to microbiological 
monitoring. 
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